Clinical Digest: Recent Clinical Trials on COVID-19 (2026-04)
To assist researchers and healthcare practitioners in staying up-to-date with the latest advancements in clinical research, the Clinical Digest Team has compiled a comprehensive list of recent clinical trials related to COVID-19. These trials are organized by their release dates for your convenience. (Last updated on: 2026-04-06)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that gets you the personalized and comprehensive updates on the latest clinical research in your field. It also empowers you to read articles, write articles, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: Recent Clinical Trials on COVID-19 (2026-04)
| Clinical Trial | Contact(s) | Updated | |
|---|---|---|---|
| 1 | The Combined Usage of Clinical Physiological Finding in Management of COVID 19 Patients PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: This study utilizes physiological indicators of COVID-19 patients as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients. This study employs simple and easy-to-use assessment methods, which can be further aided by artificial intelligence technology to facilitate early response and medication. |
CHIA-HSI CHEN; | 2026-03-31 |
| 2 | Enhancing Veterans Long-COVID Care: A Cognitive-Sensorimotor Framework to Understand Gait and Balance Dysfunction PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Growing evidence indicates that many people who have chronic post-acute sequelae of SARS-CoV-2 infection (PASC) will experience ongoing neurological and musculoskeletal impairment that can affect gait and balance. Identifying the factors contributing to these impairments and how they influence functional mobility is the first step towards creating effective evaluation and treatment protocols. In this study the investigators will examine cognition, vision, proprioception, muscle strength, … |
MATTHEW J. MAJOR; | 2026-02-10 |
| 3 | Viromes in Infants Presenting With A Septic Syndrome PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Fever in infants younger than 3 months is a common reason for emergency department visits and is associated with a significant risk of serious bacterial infections. Because it is difficult to distinguish bacterial from viral infections at presentation, management is often aggressive and includes invasive procedures, hospitalization, and empiric antibiotic therapy. Despite advances in molecular diagnostics, the etiology of fever remains unidentified in a substantial proportion of cases. This study aims to assess the presence of pathogenic viruses in respiratory and intestinal samples from febrile infants younger than 3 months compared with afebrile controls, and to explore associations with clinical, … |
UNIVERSITY HOSPITAL MONTPELLIER | 2026-03-17 |
| 4 | Dapagliflozin for Long COVID Syndrome PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months. |
IAN PATERSON; | 2026-02-20 |
| 5 | A Randomized Controlled Trial for Cervicothoracic Sympathetic Chain Block Against Sham Injection Evaluation for Post COVID Condition: The CeASE RCT PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Post-COVID Condition (PCC) affects roughly 2.1 million Canadians, carrying an annual economic burden of CAD $7.8-50.6 billion. It presents across multiple organ systems with symptoms including fatigue, brain fog, palpitations, and orthostatic intolerance, at an annual cost of CAD $1,675-$7,340 per case. A key mechanism underlying many treatment-resistant PCC symptoms appears to be dysautonomia abnormal autonomic nervous system function driven by immune-mediated sympathetic overactivity. Persistent inflammation (cytokine storms, T/B-cell dysfunction, microclots) sustains sympathetic hyperactivity, which in turn perpetuates systemic inflammation and sickness behaviors resembling PCC symptoms. Current treatments including beta blockers, ivabradine, fludrocortisone, and rehabilitation are limited by variable responses, … |
ANUJ BHATIA; | 2026-03-12 |
| 6 | Does Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID? PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Millions have developed Long COVID (LC), and recent findings show an association between taurine deficiency (an amino acid) and symptoms in LC. Cost-effective and accessible interventions are needed to improve welfare and reduce healthcare costs. We will investigate the efficacy of 12-week taurine supplementation, on vascular function and the cardio/cerebrovascular responses to upright posture in LC. We will measure resting vascular function with EndoPAT and ultrasound, resting heart rate variability, and the blood pressure, heart rate, and brain blood flow response to 5 minutes of head-up tilt before and after 12-weeks of taurine supplementation in LC. |
HEATHER EDGELL; | 2026-01-06 |
| 7 | Communication in The Hospital: Impact on Patients With Alzheimer’s Disease and Other Causes of Cognitive Impairments and Their Surrogate Decision Makers Related Papers Related Patents Related Grants Related Experts Highlight: This is a pilot study of scheduled video/audio conferences by clinical navigators on the experience of surrogate decision makers for hospitalized older adults with Alzheimer’s disease (AD), delirium, and other causes of cognitive impairment. The purpose of this study is to learn more about the experiences of surrogate decision makers of hospitalized older adults when they cannot be physically present with the patient in the hospital. We will conduct a randomized pilot study of virtual visits to connect the surrogate decision makers of incapacitated, hospitalized older adults with AD, delirium, … |
ALEXIA M. TORKE; | 2025-08-05 |
| 8 | A Phase 1, Observer-Blind, Randomized, Controlled Study to Evaluate The Safety and Immunogenicity of An Investigational MRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The study will assess any side effects or health issues, and additional blood samples will be collected at specific times to evaluate how well participants bodies build protection against the flu and COVID-19. |
DONALD BRANDON; | 2026-03-27 |
| 9 | A Phase 1a/b Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics, anti-drug antibodies, and neutralizing activity of MDX2301 administered by intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes in healthy adults and adults at higher risk for severe COVID-19. Participants will receive single IV, IM, and SC doses of MDX2301 or placebo and a repeat IM or SC dose approximately 3 months apart of MDX2301 or placebo. |
TRIAL MED; | 2026-03-04 |
| 10 | Electrostimulation Suit As A Therapeutic Tool in Post-COVID Syndrome: Effects on Physical and Functional Status. A Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Post-COVID syndrome is a condition that affects some people after recovering from the acute phase of COVID-19. Common symptoms include persistent fatigue, reduced physical capacity, and difficulties performing everyday activities, which can significantly impact quality of life and independence. At present, there is limited scientific evidence on effective rehabilitation strategies for this population. The purpose of this study is to evaluate whether the use of a whole-body electrostimulation suit can improve fatigue, physical performance, … |
MARÍA DEL PILAR RODRÍGUEZ PÉREZ; | 2025-12-31 |
| 11 | Human Factors and Clinical Validation of The CorDx Tyfast Flu A/B & COVID-19 At Home Multiplex Rapid Test Using Anterior Nares Nasal Samples for Over-The-Counter (OTC) Use PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The study’s primary objective is to evaluate the performance of the CorDx Tyfast Flu A/B \& COVID-19 At-Home Test for detecting SARS-CoV-2, Influenza A, and B in nasal samples collected by lay users, compared to 510(k)-cleared RT-PCR tests. Secondary objectives are to assess usability and instruction comprehension and reproducibility with untrained operators at Clinical Laboratory Improvement Amendments (CLIA)-waived sites. |
CORDX | 2026-02-24 |
| 12 | A Phase 1a, Single-Blind, Randomized Comparative Clinical Trial Evaluating The Impact of Vaccine Formulation on The Safety and Immunogenicity of The COV2 Vaccine in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase 1a, single-country, single-centre, single-blinded, COV2 vaccine formulation randomized trial designed to investigate and compare the safety and immunogenicity of two COV2 vaccine formulations. COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing modified SARS-CoV-2 spike protein. Participants will receive one of the two COV2 formulations in two doses on Day 0 and Day 28. This trial consists of two parts; Part 1 is a vaccination phase assessing safety and immunogenicity and Part 2 is a long-term immunogenicity follow-up assessing persistence of immune response. |
HEIKKI LÖPPÖNEN; | 2026-02-20 |
| 13 | Phase 1 Dose Ranging Study to Assess The Safety, Reactogenicity, and Immunogenicity of PepGNP-COVID19, A Synthetic Nanoparticle-based, T Cell Priming Peptide Vaccine Against SARS-CoV-2 As A Booster Dose PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This Phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of PepGNP-COVID19, a synthetic nanoparticle-based, T cell-priming peptide vaccine against SARS-CoV-2, when administered as a booster dose in healthy adults. PepGNP-COVID19 is designed to induce broad and durable T cell-mediated immune responses by delivering conserved SARS-CoV-2 peptides covalently bound to carbohydrate-coated gold nanoparticles, with the goal of enhancing tissue-resident cytotoxic T lymphocytes in the respiratory tract and reducing the need for frequent antigen updates. This randomized, participant-blinded, dose-ranging, multi-site trial will enroll 60 healthy adults aged 18-64 years, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2026-04-03 |
| 14 | A Phase 3, Randomized, Triple-Blind, Placebo-Controlled Study to Evaluate The Efficacy and Safety of VYD2311 for The Prevention of COVID-19 in Adults and Adolescents PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adults and adolescents at least 12 years old. Participants in this study will be given a study drug that will be either VYD2311 or placebo. The study drug will be given as a shot into the muscle in the participant’s upper thigh or upper arm once a month with a total of 3 shots during the study. This study will help researchers see how well VYD2311 works to prevent COVID-19 during the 90 days after the first shot. The study will also look at the safety and tolerability of VYD2311, how the study drug is processed by the body (pharmacokinetics), how the immune system reacts to the study drug (immunogenicity), and how well VYD2311 can block the virus from infecting cells (neutralization). To do these tests, your blood will be drawn at certain times during the study. |
INVIVYD | 2026-03-16 |
| 15 | Study Evaluating The Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing in The General Population in Community Settings PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Respiratory infections are very common, especially during winter, and are often caused by viruses such as influenza, SARS-CoV-2 or respiratory syncytial virus (RSV). These illnesses are generally mild, but their symptoms do not always allow a clear distinction to be made between a viral infection and a bacterial infection. In the absence of a precise diagnosis, antibiotics may be prescribed when they are not necessary in many cases. However, the excessive use of antibiotics contributes to the development of bacterial resistance, … |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2026-01-14 |
| 16 | Volatile Organic Compounds Analysis for Rapid Testing Using EXhaled Breath for Respiratory Infection PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Emerging respiratory diseases are a global health threat. Viruses such as influenza and coronaviruses have been the main cause of pandemics over the last century. In general, the impact of these respiratory infections is not limited to pandemic risks. Indeed, some pathogens also induce seasonal epidemics with a significant medical and economic burden. It is therefore essential to strengthen global surveillance, warning systems and early diagnosis capabilities for pathogens responsible for respiratory infections. One promising and recognized approach is the analysis of exhaled air, which contains a complex mixture of volatile organic compounds (VOCs), … |
ALEXANDRE GAYMARD; | 2026-01-16 |
| 17 | Volatile Organic Compounds Analysis for Rapid Testing Using EXhaled Breath for Respiratory Infection in Hospitalised Patients PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Emerging respiratory diseases represent a global threat. Viruses such as influenza and coronaviruses have been the main drivers of pandemics over the past century. More broadly, the impact of these respiratory infections is not limited to pandemic risks. Indeed, some of them also trigger seasonal epidemics with a significant medical and economic burden. Consequently, it is essential to strengthen global surveillance, and diagnostic capacities for the pathogens responsible for respiratory infections. The diagnosis of respiratory infections is even more important in cases of severe infection, … |
HOSPICES CIVILS DE LYON | 2026-01-20 |
| 18 | Efficacy of Non-invasive Neuromodulation Treatments for Post-COVID-19 Sequelae in Patients With Musculoskeletal, Respiratory and Neurological Conditions Due to Impaired Taste and Smell PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19. It will also estimate the impact of non-invasive neuromodulation treatment on the functionality and quality of life of patients with COVID-19 sequelae.The main question it aim to answer is: \- Is non-invasive neuromodulation effective as a therapy in neurological, … |
GEMA LEÓN BRAVO; | 2025-09-18 |
| 19 | SARS-CoV-2 MRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors (CoVaCheck) A Multicenter Retrospective Cohort Analysis in Austria PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A multicenter retrospective cohort analysis in Austria Primary Objective: To assess whether receiving an mRNA COVID-19 vaccine within 3 months before starting ICI (Immune checkpoint inhibitors) therapy improves best overall response (mRECIST) in HCC (hepatocellular carcinoma). Secondary Objectives: Evaluate whether vaccination within 1 or 3 months affects OS (overall survival) , PFS (Progression free survival)), or TTP (Time to progression); compare outcomes by vaccination status, vaccine type, and prior infection; explore modification by cirrhosis severity and tumor characteristics; and assess safety (irAEs, steroid use, toxicity-related discontinuation). |
FLORIAN RAINER; | 2026-01-14 |
| 20 | RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial – Effect of Hyperbaric Oxygen Therapy for The Treatment of Post COVID Condition (RECLAIM-HBOT) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The RECLAIM study platform will be used to explore whether the use of Hyperbaric Oxygen therapy (HBOT) improves the symptoms of post covid cognitive dysfunction. Hyperbaric oxygen therapy is a well-established medical treatment. HBOT promotes healing by delivering a high concentration of oxygen into the body. This high level of oxygen has a number of known benefits, such as growth of new blood vessels, as well as regulating immune and inflammation responses. It helps protect the brain and other nervous tissue from inflammation. HBOT may also have antiviral effects. Collectively, … |
RITA KATZNELSON; | 2026-02-23 |
| 21 | Incidence of Bleeding, Thrombosis and Transfusion Requirements in ICU Patients With COVID-19 Supported With Veno-venous Extracorporeal Membrane Oxygenation: A Single-center Retrospective Cohort Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The investigators aim to assess the risk of bleeding and thrombo-embolic complications as well as benefit and harm of blood product transfusion and anticoagulation therapy in adult ICU patients with COVID-19 supported with V-V ECMO |
VIBEKE LIND JØRGENSEN; | 2026-01-29 |
| 22 | Unravelling Health and Frequent Symptoms and Voice Characteristics Evolution Over Time of Users of The Long COVID Companion Application to Develop Voice Biomarkers of Frequent Long Covid-related Symptoms PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The LIH DDP research team focuses its research topics on vocal biomarkers and Long COVID, among others. Voice is indeed a promising tool to monitor health, as it contains many information on our health and is easy to collect. The development of vocal biomarkers of Long COVID-related symptoms could improve the remote monitoring of the health status of people affected by this disease. The LIH developed the Long COVID Companion (LCC) app in collaboration with the ApresJ20 Long COVID patient association in France to support patients in their daily lives. LCC app users will be invited to participate in this study to collect voice recordings at the same time as health-related data. The objectives of this study are: Primary objective: To develop vocal biomarker candidates for the main Long COVID symptoms (fatigue, brain fog, respiratory problems, sleep issues, stress, anxiety,..) in a population of people with Long COVID. Secondary objectives: * to assess the intra-individual longitudinal evolution of voice characteristics of people with LC * to assess app usability and acceptability in the long-term. |
AURÉLIE FISCHER; | 2025-12-08 |
| 23 | A Phase 4 Pragmatic, Randomized Trial to Evaluate The Effectiveness of MRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection. Participants will be randomized 1:1 to either COVID-19 vaccine or no COVID-19 vaccine. |
TOR BIERING-SØRENSEN; | 2026-03-16 |
| 24 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL STUDY EVALUATING THE SAFETY, TOLERABILITY, IMMUNOGENICITY AND EFFICACY OF A VARIANT-ADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don’t have any serious health problems, compared to a group that receives a vaccine that doesn’t contain an ingredient to protect against COVID-19 (placebo). |
BIONTECH SE | 2025-12-24 |
| 25 | Development of A Personalized Alternative Non-invasive Rapid Diagnostic Test for SARS-CoV-2 in Patients With Long COVID PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a diagnostic clinical investigation designed to evaluate bioelectrical response patterns assessed by electro-acupuncture-based medicament testing. The method is used to identify individual bioelectrical reactivity associated with the presence and persistence of pathological factors and to assess patient-specific responses to tested medicinal substances. The study involves a single-session, non-invasive diagnostic procedure without administration of pharmacological treatment. The primary objective is the methodological evaluation of the diagnostic approach and the characterization of the detected bioelectrical response patterns in the studied population. |
NAYLYA DJUMAEVA; | 2026-01-15 |
| 26 | Multiparametric Total-Body [18F]F-AraG PET/CT Imaging in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study uses total-body \[¹⁸F\]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET/CT imaging along with blood biomarker assessments and symptom evaluations. The study aims to characterize sites of immunological perturbation, correlate PET imaging findings with peripheral blood markers, and evaluate longitudinal changes in tissue-based immune activity in relation to symptom patterns over time. Data from this study will improve understanding of tissue-level immune dysregulation in PASC and support future clinical tools for assessing and managing this condition. |
NEGAR OMIDVARI; | 2026-02-02 |
| 27 | Clinical and Socioeconomic Characteristics of Suicidal Behaviour in Children and Adolescents During The Covid19 Pandemic Period in Auvergne-Rhône-Alpes. Prospective Quantitative and Qualitative Study PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: In 2020, the world is hit by a global health crisis due to a pandemic following the appearance of Sars-cov-2 or covid-19. This pandemic was accompanied by a constant fear of contamination and death, relayed by the media. In France, the government proposed in response to the arrival of this virus on French territory. This policy was implemented in different ways over 3 distinct periods: strict containment at the start of the epidemic, then a lighter one, … |
ELISE MAMIMOUE; | 2025-12-24 |
| 28 | Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024 PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Due to the lower virulence of circulating Omicron variants and the high seroprevalence of anti-SARS-CoV-2 antibodies, the incidence of cases and deaths related to the SARS-CoV-2 virus has significantly decreased in recent months worldwide. However, these infections remain a major public health problem in severely immunocompromised patients, who have decreased vaccine efficacy and are at higher risk of persistent SARS-CoV-2 viral shedding, relapses, secondary invasive fungal infection, intensive care unit hospitalization, and death than non-immunocompromised patients. The research concerns adult patients at very high risk of severe SARS-CoV-2 disease, … |
CLÉA MELENOTTE; | 2025-09-12 |
| 29 | Long-Term Clinical and Health Effects of Previous COVID-19 in Patients Presenting for Preoperative Anesthesia Evaluation PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The COVID-19 pandemic has resulted in persistent health problems in a significant proportion of individuals after recovery from the acute infection. These long-term manifestations, commonly referred to as post-COVID condition or long COVID, may involve respiratory, cardiovascular, neurological, psychological, and general health domains. Understanding these sequelae is particularly important in patients undergoing preoperative anesthesia evaluation, … |
OĞUZ KAĞAN BULUT; | 2026-02-27 |
| 30 | Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients: A Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This randomized controlled study evaluates the effects of cold water hydrotherapy in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to an usual care setting without hydrotherapy treatment. |
REMBERT KOCZULLA; | 2025-12-02 |
| 31 | A Phase 4, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate The Efficacy and Safety of MRNA-1283 And MRNA-1273 Variant-Containing Formulation in Adults 50 to 64 Years of Age Without Underlying Conditions That Put Them at High Risk for Severe Outcomes From COVID-19 PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID-19. |
MODERNATX | 2026-03-12 |
| 32 | Interleukin-15 Superagonist Nogapendekin Alfa Inbakicept in Participants With Long Covid PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests. |
MICHAEL PELUSO; | 2026-03-27 |
| 33 | IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine. |
EDWARD MITRE; | 2025-12-17 |
| 34 | A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Post-Marketing Study to Evaluate The Efficacy and Safety of An Omicron JN.1 Subvariant SARS-CoV-2 RS Vaccine Adjuvanted With Matrix-M® in Adults 50 to < 65 Years of Age Without High Risk Conditions for Severe COVID-19 PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for 180 days. |
NOVAVAX | 2025-07-25 |
| 35 | Definition of Sub-phenotypes of Pneumonia Based on The Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Pneumonia remains a leading cause of antibiotic consumption globally, contributing significantly to the burden of antimicrobial resistance (AMR). The respiratory microbiome plays a crucial role in the emergence of AMR and therapeutic failure in both community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). The PHENOMENON study aims to investigate the relationship between the respiratory microbiome composition and clinical outcomes to improve the prediction of treatment failure and AMR emergence. Methods: This multicenter prospective cohort study will include 300 adult patients across three cohorts: CAP in general wards, severe CAP in intensive care units (ICU), … |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2025-11-24 |
| 36 | A Double-blind, Randomized, Controlled, Phase 2a Study to Evaluate The Safety and Tolerability of A Newcastle Disease Virus-based Mucosal Vaccine (NDV-HXP-S-KP.2) Relative to An Approved Systemic MRNA Vaccine in Previously Vaccinated Adults PF:3 Related Papers Related Patents Related Grants Related Experts Abstract: This is a double-blind (supported by a double-dummy design), randomized, active comparator-controlled Phase 2a safety and tolerability study. The study will enroll approximately … |
DEIRDRE BURKE; | 2025-11-06 |
| 37 | Clinical Validation of The Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The Metrix Respiratory Panel Test will be evaluated for use in Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g., urgent care facilities). This will be a prospective study conducted at three or more investigational sites located within the United States for the clinical validation of the Metrix Respiratory Panel Test for the detection of SARS-CoV-2, Influenza A, Influenza B, Respiratory syncytial virus, … |
BRAD W KILLINGSWORTH; | 2025-10-16 |
| 38 | Development of Virtual Reality Treatment Technology to Treat Trauma Related to COVID-19 Infection PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This clinical trial aims to develop and evaluate the effectiveness of virtual reality (VR)-based exposure therapy for trauma symptoms related to COVID-19 infection. The intervention targets healthcare workers and individuals from the general population who experienced pandemic-related psychological distress. The study assesses psychological and physiological outcomes, including PTSD, anxiety, depression, HRV, and EEG biomarkers. |
JI SUN KIM; | 2025-10-09 |
| 39 | START: Design and Validation of Innovative Strategies Based on Dual-Task Approach for Neuro- Rehabilitation Technologically-supported in People With Chronic Neuro-inflammatory Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: People affected by Stroke, Multiple Sclerosis (MS), and Parkinson’s disease (PD) share severe and complex disabilities. Widespread neuro-inflammatory processes represent an important pathogenetic component in all three conditions. The potential overlap with neurological complications of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has further contributed to the worsening of functional impairment. Since pharmacological therapies have limited or negligible effects in these disorders, neurorehabilitation plays a crucial role in restoring and maintaining adequate functional abilities. In this context, dual-task strategies have attracted growing interest, … |
MARCO IOSA; | 2025-12-11 |
| 40 | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BNT162b2 (LP.8.1)-ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID-19 PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19, called BNT162b2 (2025/2026 formulation). This study is seeking participants 5 through 11 years of age who: * have at least 1 underlying condition that puts them at high risk for severe outcomes from COVID-19, * and are medically stable. All participants in this study will receive 1 vaccine dose given in the muscle of their arm of a BNT162b2 (2025/2026 formulation) vaccine which targets the COVID-19 virus, … |
BIONTECH SE | 2026-02-11 |
| 41 | A Real-world Study on The Effectiveness of Nirmatrelvir-ritonavir in Reducing Severe Outcomes From COVID-19 PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to learn about the effects of the study medicine called Paxlovid \[nirmatrelvir-ritonavir/PF-07321332\], for the potential treatment of COVID-19. This study will use patient health records in Ontario, to find people who were sick with COVID-19 and visited a pharmacist to be treated, anytime from December 1st, 2022, to March 31st, 2024. To be included in our study, … |
PFIZER | 2025-12-04 |
| 42 | A Phase 1/2A, Randomized Study of A T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64. The CoTend-s3BXBB vaccine includes a component called s3, which was designed to improve the body’s response to the vaccine. CoTend-BXBB is the same vaccine without s3. The main questions the study aims to answer are: 1) Is the investigational vaccine safe? 2) Does s3 lead to bigger, broader, and longer-lasting responses to the vaccine? 5 different doses of the vaccines will be studied. Participants will receive a single dose of either CoTend-s3BXBB, CoTend-BXBB, … |
KARA CHEW; | 2025-10-31 |
| 43 | A Phase 3 Open-Label, Single-Arm Study to Evaluate The Safety and Immunogenicity of An Omicron JN.1 Subvariant SARS-CoV-2 RS Vaccine Adjuvanted With Matrix-M PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120 participants. This includes adults aged 65 and older, … |
SANOFI | 2026-02-13 |
| 44 | A Description of The Proportion, Genotype Distribution of Respiratory Syncytial Virus and The Severity of Disease in Hospitalized Elderly in Vietnam PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This observational, prospective, multicenter study aims to estimate the proportion of RSV infection in adults aged 60 years and older hospitalized due to acute respiratory infections or exacerbation of cardiopulmonary disease. |
TAM ANH RESEARCH INSTITUTE | 2025-11-20 |
| 45 | Reducing Respiratory Virus Transmission in Bangladeshi Classrooms PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: This study will test if affordable air cleaning devices (box fans with a filter attached and/or ultraviolet light lamps) installed in classrooms can reduce the number of viral respiratory illnesses schoolchildren experience. |
STEPHEN P LUBY; | 2025-04-02 |
| 46 | Reactogenicity, Patient Reported Outcomes and Vaccine Preference in Adults Immunized With Recombinant Protein or MRNA COVID-19 Vaccines PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mNEXSPIKE mRNA-1283 vaccine. Specifically, the study aims to determine the rate of participant-reported symptoms associated with each type of vaccine. |
MARCEL CURLIN; | 2026-03-04 |
| 47 | Study of Pneumococcal Carriage in RSV Bronchiolitis in Infants Aged 6 to 18 Months PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The relationship between RSV (human respiratory syncytial virus) infections and invasive infections or pneumonia caused by Streptococcus pneumoniae has been observed epidemiologically for several years. Few fundamental data exist to support the epidemiological relationship. This study will investigate the proportion of pneumococcal carriage in RSV-infected infants and noninfected infants (proportion, serotype profile). |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2025-05-15 |
| 48 | Imbalances of Regional Pulmonary Ventilation in Patients With Post-acute-COVID-19 Symptoms PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Investigation of the correlation of CT-morphological changes of the lung compared to regional ventilation distribution on electrical impedance tomography in patients with post-acute-Covid-19 symptoms. |
JAN-CHRISTOPH LEWEJOHANN; | 2025-09-25 |
| 49 | Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this research is to evaluate an innovative treatment, Bevacizumab, in patients suffering from respiratory complications related to COVID-19. These complications, particularly difficulty breathing (dyspnea) and impaired lung function, are common in some individuals after infection. The study seeks to determine whether Bevacizumab can improve breathing capacity by acting on vascular mechanisms that may be responsible for these issues. A total of 21 patients with these persistent symptoms will be included in the study, … |
JEAN SÉBASTIEN HULOT; | 2025-07-28 |
| 50 | Physical Rehabilitation of Long COVID By Heat Therapy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Post-acute sequelae of SARS-CoV-2 infection (PASC) is becoming a major risk factor for chronic diseases, with older adults and those with underlying health conditions at risk of developing persistent mobility limitations and disabilities. Although exercise intervention is a common strategy to restore functional capacity, it may not be feasible or enticing to many people with PASC. This clinical trial seeks to establish the tolerability and efficacy of at home lower-body heat therapy for improving functional capacity along with metabolic and vascular health in late-middle aged and older adults with PASC, also known as long COVID. |
GWENAEL LAYEC; | 2025-10-23 |
| 51 | A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate Safety and Efficacy of Ratutrelvir and Standard of Care in Non-hospitalized Symptomatic Adult Participants With Mild to Moderate COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results. |
TRAWS PHARMA | 2026-01-21 |
| 52 | Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer: A Historical Cohort Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study was designed as a single-center retrospective analysis aimed at investigating whether COVID-19 infection increases the risk or burden of radiation-induced pneumonitis in breast cancer patients. |
ZHEJIANG HOSPITAL | 2025-09-23 |
| 53 | LC-REVITALIZE – A Long Covid Repurposed Drug Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three months. The main goal of the study is to determine whether the drug treatments can improve symptoms in five key areas: 1) fatigue, 2) breathing, 3) memory, thinking, and communication, 4) muscle and joint pain, and 5) circulation. A secondary goal is to assess changes in the body, such as reducing inflammation, … |
DOUGLAS D. FRASER; | 2026-04-03 |
| 54 | Single Arm Study to Evaluate The Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over. |
CHAITALI NANGIA; | 2025-10-21 |
| 55 | Evaluation of Spatiotemporal Associations Between The COVID-19 Pandemic and The Incidence of Cancer Diagnoses in Bavaria, Germany: A Registry-based Study (PanSCan) PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: The COVID-19 pandemic has placed a significant strain on healthcare systems worldwide and has also impacted the diagnosis and treatment of cancer. In Germany, there was a notable decline in cancer diagnoses during the pandemic, partly due to delays in early detection and limited access to medical treatments. This study examines how the number of cancer cases in Bavaria changed before and during the pandemic, taking various factors into account, such as the socioeconomic status of different regions, the age of affected individuals, … |
JACQUELINE MÜLLER-NORDHORN; | 2026-01-06 |
| 56 | Perioperative Outcomes for Children With Preoperative Upper Respiratory Tract Infection Symptoms in Elective Non-cardiac Surgery After COVID-19 Pandemic at A Large Tertiary Hospital in China: A Retrospective Cohort Study PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this observational study is to investigate the impact of the COVID-19 pandemic on perioperative outcomes in children with preoperative URTI symptoms and to explore whether the COVID-19 pandemic affected the additional surgical risk associated with preoperative URTI symptoms. The main question it aims to answer is the appropriate timing of elective non-cardiac surgery in the post-COVID-19 era. |
AIJUN XU; | 2025-11-21 |
| 57 | Effectiveness of Metabolic Modulation in Treating Post-vaccination Syndrome: A Prospective Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to evaluate whether metabolic modulation with a combined nutraceutical product can improve symptoms and metabolic health in adults diagnosed with post-acute Covid-19 vaccination syndrome (PACVS), a condition characterized by persistent fatigue and exercise intolerance attributed to Covid-19 vaccination and confirmed by laboratory testing. The main questions it aims to answer are: Does the combined nutraceutical intervention improve quality of life (measured by the PAC-19QoL questionnaire) in PACVS patients? Does the intervention improve metabolic, inflammatory, and functional biomarkers (e.g., HbA1c, blood lactate, CRP, spike protein levels, heart rate variability, … |
INDEPENDENT MEDICAL ALLIANCE | 2025-05-13 |
| 58 | A Phase I-II, Blinded, Randomized, Placebo-controlled Study of A T Cell Priming Next-generation Vaccine Against Coronavirus Disease in Healthy Adults PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The study aims to investigate the safety and immunogenicity of one dose vs two doses of a T-cell priming next-generation vaccine against Coronavirus disease. |
ALBERTO R EDISON; | 2025-02-24 |
| 59 | Study of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of The Drug B10-FC – Study Drug for Early Etiotropic Therapy of Coronavirus Infection Caused By The SARS-CoV-2 Virus, Using Heavy-chain Humanized Monoclonal Antibodies, After Single Administration to Adult Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A two-stage open-label, prospective, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity study with participation of healthy volunteers in three dose-escalation groups and patients with a confirmed diagnosis of COVID-19. |
GAMALEYA RESEARCH INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY HEALTH MINISTRY OF THE RUSSIAN FEDERATION | 2025-09-05 |
| 60 | Safety and Efficacy of 10-day Course of Remdesivir to Prevent Severe COVID-19 in Asymptomatic or Paucisymptomatic SARS-COV-2-positive Kidney Transplant Recipients: A Single-arm Proof-of-concept Interventional Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Since the start of the COVID-19 pandemic, the approach to solid organ transplantation has evolved. Transplants using organs (excluding lungs) from COVID-19-positive donors have shown short-term safety, but there is limited data on recipients who are SARS-CoV-2 positive. Currently, kidney transplants in such recipients are delayed until symptoms resolve and a negative PCR is preferred, … |
FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA | 2025-09-29 |
| 61 | COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to find out whether the COVID pandemic has affected participants’ current physical activity, fitness, blood pressure, sleep, and mental stress to better understand its long-term health effects. To complete this study, participants will visit the Neurovascular Physiology Laboratory (NVPL) at the Indiana University School of Public Health Bloomington two times, requiring a total commitment of about 6 hours. Visit 1 involves completing screening questionnaires, a consent document, and additional questionnaires about participant health behaviors (e.g., sleep and physical activity) and general mental and physical health. After the visit, … |
AUSTIN ROBINSON; | 2025-10-30 |
| 62 | Study of The Neutralizing Power of Serum Antibodies – 2 (PNAS-2) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received. |
THIERRY PRAZUCK; | 2025-12-19 |
| 63 | Effects of Kneipp Hydrotherapy During Inpatient Post-Covid-19 Rehabilitation: A Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This randomized controlled study evaluates the effects of cold water hydrotherapy as an adjunct to standard rehabilitation in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to standard rehabilitation alone. |
ANDREAS REMBERT KOCZULLA; | 2025-08-28 |
| 64 | Impact of Nirmatrelvir and Ritonavir (PAXLOVID®) on Mortality, Progression to Severe Disease, and Activities of Daily Living (ADL) Worsening in Long-term Care Hospitals (LTCHs) in Korea PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to learn about the effects of the study medicine (called Paxlovid) for the possible treatment of COVID-19 in older adults who live in long-term care hospitals (LTCHs) in Korea. Researchers want to know whether Paxlovid lowers the chance of severe illness or death and helps people carry out their usual daily activities, remain free from aging and weakness, … |
PFIZER | 2025-07-28 |
| 65 | A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, CROSSOVER STUDY TO DETERMINE THE BE OF NIRMATRELVIR FOLLOWING ORAL ADMINISTRATION OF FDC TABLETS RELATIVE TO THE PAXLOVID® COMMERCIAL TABLETS IN HEALTHY ADULT PARTICIPANTS UNDER FASTED CONDITIONS Related Papers Related Patents Related Grants Related Experts Highlight: Medicines that may have different names or be made in different ways but have the same effect on the body are called bioequivalent. The purpose of this study is to learn about the bioequivalence of nirmatrelvir plus ritonavir after taking 2 different combination tablet forms by mouth. These combination tablets are compared to the tablet formulation that is already in the market. This study will be done under fasted conditions in healthy adult participants. This study is seeking participants who are: * Male and non-pregnant female participants aged 18 years and above. * with a body weight of more than 50 kilograms and Body Mass Index (BMI) between 16 to 32 kilograms per meter squared. * are healthy as confirmed by medical history, physical examination, laboratory tests. The study will also look at the safety and tolerability of nirmatrelvir plus ritonavir combination tablet and marketed tablet formulations in healthy adult participants. The study will consist of 4 treatments: Treatment A: Single oral dose of nirmatrelvir plus ritonavir 150 (1 × 150)/100 milligrams marketed tablets under fasted conditions (Reference 1) Treatment B (low dose strength): Single oral dose of nirmatrelvir plus ritonavir 150/100 milligrams (2 × \[75/50 milligrams\]) combination tablets under fasted conditions (Test 1) Treatment C: Single oral dose of nirmatrelvir/ritonavir 300 (2 × 150)/100 milligrams marketed tablets under fasted conditions (Reference 2) Treatment D (high dose strength): Single oral dose of nirmatrelvir/ritonavir 300/100 milligrams (2 × \[150/50 milligrams\]) combination tablets under fasted conditions (Test 2) All treatments will be given under fasted conditions. Fasted condition means the participants would not have had anything to eat before taking the medicines. Around 28 participants will be enrolled in the study. Healthy participants will be tested to see if they can be in the study within 28 days before receiving the study medicine. Selected participants will be admitted to the clinical research unit (CRU) one day before receiving the study medicine and will remain in the CRU until discharge after completing all the treatment periods. On Day 1 of each period, participants will be given a single dose of study medicine nirmatrelvir/ritonavir 300/100 mg or 150/100 mg by mouth by chance. Study medicine will be given with approximately 240 milliliters of room temperature water under fasted conditions (overnight fast of at least 10 hours and no food until 4 hours after receiving the study medicine). Blood samples will be collected at different times of the day up to 48 hours after taking the study medicine. Participants will be discharged from the CRU on Day 3 of Period 4, after all the study related procedures have been completed. A follow-up call will be made to participants around 28 to 35 days from receiving the final dose of the study medicine. The study will look at the experiences of participants receiving the study medicine. This will help to understand if the study medicine is safe and effective. |
PFIZER | 2025-12-26 |
| 66 | A Phase 1 Dose Escalation Study to Assess The Safety, Reactogenicity, and Immunogenicity of STX-S for Prevention of SARS-CoV-2 Infection As A Booster Dose PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of STX-S in adults who have previously received a primary series and at least one booster with an authorized or licensed SARS-CoV-2 parenteral vaccine. The study is designed as a non-randomized, open-label, dose-escalation clinical trial evaluating three dose levels of STX-S. A sample size of 60 participants (20 participants per dose cohort) is anticipated. The primary objective is to evaluate the safety and reactogenicity of a single intramuscular (IM) injection of three different dose levels (25 ng, 50 ng, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2026-02-06 |
| 67 | RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial – Effect of Hi-OxSR for The Treatment of Post COVID Condition (RECLAIM-HiOxSR) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The RECLAIM study platform will be used to explore whether the use of the Hi-OxSR device improves the symptoms of post covid cognitive dysfunction. Carbon dioxide (CO2) has been proposed as a potential treatment for persistent immune activation as there is evidence that CO2 has antioxidant, anti-inflammatory, and anti-cytokine effects. We conducted a pilot study assessing the open label use of re-breathing CO2 (using Hi-OxSR) twice a day for 14 days, … |
ANGELA M CHEUNG; | 2025-09-15 |
| 68 | Phase 1 Study of A Long-acting Injectable S-892216 in Healthy Adult Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults. |
SHIONOGI | 2025-08-27 |
| 69 | Evaluation of A Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms: A Pragmatic, Interventional Clinical Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19. Participants will receive the combined quercetin/curcumin supplement for 2 months. The primary outcome is the improvement in overall symptom burden, while secondary outcomes include changes in quality of life, the need for NSAIDs, and inflammatory markers. The study seeks to provide real-world evidence of the potential benefits of this combined supplement in managing Long COVID-19 symptoms. |
AMJAD KHAN; | 2025-12-19 |
| 70 | A Phase 3b/4, Open-label Study to Evaluate The Immunogenicity and Safety of MRNA-1283 COVID-19 Variant-containing Vaccine Formulations PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the immunogenicity and safety of the recommended variant-containing formulations of mRNA-1283 COVID-19 vaccine (mNEXSPIKE®) within the current epidemiological environment. |
MODERNATX | 2025-10-14 |
| 71 | AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE IBUZATRELVIR IN ADULTS WITH SYMPTOMATIC COVID-19 WHO ARE SEVERELY IMMUNOCOMPROMISED PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who are non-hospitalized or are hospitalized for observation or study intervention administration but do not require supplemental oxygen for COVID-19. |
PFIZER | 2026-03-04 |
| 72 | A Phase 3 Protocol to Investigate The Safety, Tolerability, and Immunogenicity of BNT162b2 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants 12 Through 64 Years of Age Considered at Higher Risk of Severe COVID-19, and Participants ≥65 Years of Age PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19. This study is seeking participants 12 through 64 years of age who are considered to be at higher risk for severe COVID-19 disease per study protocol and those 65 years of age and older. All participants in this study will receive 1 shot to their arm of a BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) 30 µg RNA-based vaccine which targets a circulating variant of SARS-CoV-2 and is selected for the 2025-2026 COVID-19 respiratory virus season. This study is about 6 months for each participant. Participants will either be enrolled in Cohort 1 (Groups 1 and 2) or Cohort 2 (Groups 3 and 4). Participants enrolled in Cohort 1 will have at least 4 visits and participants enrolled in Cohort 2 will have at least 3 visits. |
BIONTECH SE | 2025-12-22 |
| 73 | Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation (MANIFEST) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to test whether a type of rapid outpatient brain stimulation that uses magnetic fields, called accelerated intermittent theta burst stimulation (iTBS), can treat symptoms such as brain fog, depression, and anxiety in patients with Long COVID. The main questions it aims to answer are: * Is iTBS effective and feasible for reducing Long COVID symptoms? We will measure these symptoms using the Symptom Burden Questionnaire. * Are there changes in inflammatory brain chemicals associated with treatment with iTBS? We will be looking at levels of choline in the brain, … |
DAVIN QUINN; | 2025-07-15 |
| 74 | Vale+ Tu Salud: Corner-Based Randomized Trial to Test A Latino Day Laborer Program Adapted to Prevent COVID 19 PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to determine the cultural, socioeconomic, inter/personal and work-related factors that influence COVID 19 mitigation practices including social distancing, hand-washing and Personal protective equipment (PPE) use, to adapt, implement, and test Vale+Tú Salud in a cluster randomized trial to assess the extent to which LDL report increased adherence with COVID 19 mitigation practices 1 month post intervention and to promote Vale+Tú Salud just-in-time results and increase its capacity to rapidly disseminate findings among groups that serve LDL and other Latino immigrants. |
MARIA EUGENIA FERNANDEZ-ESQUER; | 2025-08-26 |
| 75 | Evaluating A Community-Led COVID-19 Testing Intervention to Address Mistrust – Study 2 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this adapted intervention study is to assess how community-led group discussions about health-related topics may alter beliefs and intentions regarding healthcare recommendations, such as COVID-19 testing and vaccination. |
KELLI J. ENGLAND; | 2026-02-27 |
| 76 | Clinical Feasibility of The BinaxNOW™ COVID-19/Flu A&B Combo in The Southern Hemisphere PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The study is designed as a clinical feasibility, to investigate the positive and negative percent agreement (PPA and NPA) of the BinaxNOW™ COVID-19/Flu A\&B Combo against a highly sensitive PCR method(s) in symptomatic patients suspected of SARS-CoV-2 or influenza infection when nasal swabs are self-collected by the patient/lay user. |
ABBOTT RAPID DX | 2025-04-15 |
| 77 | A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of PDI204 As Intravenous Infusion or Intramuscular Injection in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if a new drug called PDI204, developed for treating or preventing COVID-19, is safe and well-tolerated in healthy volunteers. This is a first-in-human study. The main questions it aims to answer are: Is PDI204 safe and well-tolerated in healthy people? How long for and how does the body interact with PDI204? Researchers will compare side effects in people who receive PDI204 and in those who receive a placebo (a look-alike substance that contains no drug) to see if and how many side-effects there are with PDI204. Researchers will also measure how long PDI204 can be detected in the blood. Participants will be asked to receive a single dose of PDI204. Participants will have to stay in the clinical center for the day of receiving the dose of PDI204 and will be discharged the next day. Participants will then need to come back to the clinical center for study visits on days 3, 5, 7 (+/-1), 15 (+/-1), 30 (+/-3), 60 (+/-3) and 90 (+/-7). |
STEPHEN KENT; | 2025-12-01 |
| 78 | PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have long-term symptoms that affect the brain. These include headaches; loss of taste and smell; sleep problems; thinking problems; depression; … |
ROBERT B INNIS; | 2026-03-03 |
| 79 | A Phase 1/2a Multicenter Trial to Evaluate The Safety and Immunogenicity of The CD40.Pan.CoV Vaccine, Adjuvanted or Not, As A Booster in Adult Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The clinical trial is a phase1/2a, open-label, dose-escalating, multicentre trial evaluating the safety and immunogenicity of the CD40.Pan.CoV vaccine, adjuvanted or not, as a booster injection in adult participants in France. 48 participants divided into 4 cohorts will be included in the trial. Primary objectives are the following: * To determine the safety and reactogenicity of different doses (0.25 mg and 1 mg) of a booster of a CD40.Pan.CoV vaccine, adjuvanted or not, … |
ANRS EMERGING INFECTIOUS DISEASES | 2026-04-01 |
| 80 | Effectiveness of Treating Post-COVID-19 Conditions (Long COVID) With The SARS-CoV-2 Specific Monoclonal Antibody, Sipavibart PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID. |
NANCY KLIMAS; | 2025-08-05 |
| 81 | Second Prospective Cohort of Patients Entering The Multidisciplinary Care Pathway for Post-Covid Syndromes – SyPoCo2 Cohort PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The study aims to identify clinical profiles of long-COVID patients and correlate them with immunological and molecular data in order to identify prognostic biomarkers and potential therapeutic targets. |
HOSPICES CIVILS DE LYON | 2026-01-21 |
| 82 | Attention, Memory, Self-reflection and Insight, and Quality of Life in Post-COVID-19 Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The pandemic has highlighted social, economic, educational, and political issues that have affected the health and quality of life of millions of Brazilians. Currently, attention and memory impairment remains predominant among the cognitive symptoms of Coronavirus observed in adults. The persistance of the reffered impairment after 12 weeks of COVID-19 is known as cognitive impairment in post-COVID-19 syndrome. Despite studies indicating the negative effects of COVID-19 on attention and memory, … |
JADE CARVALHO DA SILVA; | 2025-06-12 |
| 83 | Phase 2 Study of S-892216 in Participants Infected With SARS-CoV-2 PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of this study is to investigate the antiviral effect of S-892216 in participants with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. |
SHIONOGI | 2025-09-30 |
| 84 | The Impact of Balance Training on Functional Performance and Fall Risk in Community-Dwelling Older Adults Following Recovery From COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This research investigates the impact of balance training on improving functional performance and reducing fall risk in community-dwelling older adults who have recovered from COVID-19. Post-COVID-19, many elderly individuals experience lingering physical impairments, including muscle weakness, decreased coordination, and balance deficits, which increase their vulnerability to falls. The study evaluates whether a structured balance training program can enhance stability, mobility, and overall quality of life in this population. |
MARIAM ELSAYED MOHAMED ABD ALAAL; | 2026-01-06 |
| 85 | Conducting An Initial Small, Controlled Clinical Pharmacology Trial to Assess for Therapeutic Biologics Activity (Proof-of-Concept) That Suggests The Potential for Clinical Benefits of COVID-19 Patients With Controlled Cancers PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients with controlled cancers. 1. Treat Infection of Multiple Gene Mutation COVID-19 Virus Strains. 2. Activate Human Antigen Presentation Reaction to COVID-19 Specific Antigen. 3. The human antigen presenting cells (APCs) can take up and process COVID-19 target antigen protein into small peptide fragments, and then COVID-19 virus can be killed by APCs directly. |
HAN XU; | 2025-06-11 |
| 86 | Development of A High-throughput Serological Testing Platform for Mass Screening Purposes of Both Pediatric and Adult Cohorts- Adult Cohort PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: In the case of large emergency serosurveys, innovation in the sampling techniques is an often neglected, but relevant aspect to facilitate the enrolment of subjects in both adult and paediatric populations. Further, … |
FRANCESCO BONFANTE; | 2025-04-23 |
| 87 | A Diet Intervention Study To Mitigate Fatigue Symptoms And To Improve Muscle And Physical Function In Older Adults With Post-Acute COVID-19 Syndrome PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of this study is to conduct a 16-week randomized controlled trial aimed at investigating the effectiveness of the Whole-Diet Approach when following a healthy US-style diet rich in anti-inflammatory properties. The study will focus on evaluating its impact on reducing symptoms related to Post-Acute Sequelae of SARS-CoV-2 Infection (PACS) in adults aged 50 years and older. The main research questions this study aims to answer are: 1. Does adhering to a healthy US-style diet, which is abundant in anti-inflammatory properties, effectively mitigate fatigue symptoms in adults with PACS? 2. Does adhering to a healthy US-style diet, … |
GALYA BIGMAN; | 2025-07-11 |
| 88 | Randomized, Controlled, Multicenter Phase I/II Study Comparing The Safety and Immunogenicity of A Booster Dose of An Intranasal COVID-19 Vaccine Expressing SARS-CoV-2 N/S Recombinant Proteins With A Booster Dose of COVID-19 MRNA Vaccine in Healthy Adults (MUCOBOOST) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This Phase I/II trial in France evaluates safety and immunogenicity of a booster dose of an intranasal COVID-19 vaccine (LVT-001) versus a booster dose of a COVID-19 mRNA vaccine (Pfizer-BioNTech) in healthy adult volunteers. As a first-in-human trial, Phase I will assess the safety and immunogenicity of three escalating doses of the LVT-001 vaccine across 3 cohorts of 12 volunteers per dose level. Based on cumulative data collected up to Day 28 visit from the last included participant in the Phase I, … |
ANRS EMERGING INFECTIOUS DISEASES | 2025-12-18 |
| 89 | From Inflammation Biomarkers to Remoddeling (FAPI PET/CT) Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Rationale: The diagnosis and pathogenesis of long COVID remains unknown. We have previously shown that \[68Ga\]FAPI Positron Emission Tomography-Computed Tomography (PET/CT) imaging shows potential for diagnosis and molecular understanding of this syndrome. We have previously shown that fibroblast activation protein (FAP) can be imaged in the lung, muscle and nasopharynx of long COVID patients (with dyspnea and fatigue). However, these preliminary data are derived from a selective group of patients with long COVID after critical COVID-19. We aim to explore the generalizability of these findings in patients with long COVID with dyspnea and fatigue, … |
J PILLAY; | 2025-04-04 |
| 90 | Effectiveness and Acceptability of The Unified Protocol for The Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This Randomized Controlled Trial (RCT) aims to assess the effectiveness and acceptability of the Unified Protocol (UP) in an online group format for the treatment of emotional disorders in adults. Participants will be 90 adults (45 in the control group and 45 in the experimental group) with diagnosis of long COVID and comorbid emotional disorders. Participants will be recruited at Hospital Royo Villanova from Zaragoza, Spain. In this study it will be explored whether the changes obtained after the intervention in emotional disorders and cognitive complaints are maintained over 12 months. Additionally, … |
JORGE JAVIER OSMA LÓPEZ; | 2025-05-22 |
| 91 | Systems Biology of A MRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Given Via Intradermal (ID) Injection Using Tropis Needle-Free Injection System (NFIS) or Intramuscular (IM) Injection Using Needle and Syringe PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to determine if immune responses differ when the mRNA COVID-19 vaccine is given through different delivery methods, including a needle-free injection system, or via intramuscular injection using needle and syringe |
PHARMAJET | 2025-04-15 |
| 92 | Osteopathic Manipulative Therapy(OMT) Effects on Post-Acute Sequalae of COVID-19(PASC) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is investigating the effects of using an Osteopathic Manipulative Therapy (OMT) treatment protocol that was shown to statistically improve smell in individuals suffering from Long-COVID olfactory (smell) dysfunction in a small single-blinded pilot trial conducted during 2021. The questions this study is trying to answer are: 1. Does this OMT protocol improve other non-smell related Long-COVID symptoms 2. Do 2 OMT treatments improve Long-COVID symptoms more than 1 OMT treatment Participants will: 1. Week 1: Take an digital survey regarding their Long-COVID symptoms undergo Long-COVID OMT treatment or a placebo treatment 2. Week 2: Take an digital survey regarding their Long-COVID symptoms then all will undergo Long-COVID OMT treatment 3. Week 3: Take an digital survey regarding their Long-COVID symptoms 4. Week 8: Take an digital survey regarding their Long-COVID symptoms |
MICHAEL STENTA; | 2025-03-19 |
| 93 | Routine Application of Point-of-care PCR Test to Identify and Direct Therapy for Acute Respiratory Infection in The Emergency Department (RAPID-ARIED) Trial PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The RAPID-ARIED Trial is a pragmatic, single-centre, parallel group, open-label, randomised controlled trial to be conducted in the Accident and Emergency Department of Queen Mary Hospital in Hong Kong. The investigators aim to 1) to evaluate the clinical impact of the routine application of point-of-care polymerase chain reaction (PCR) testing for targeted respiratory pathogens in the emergency department (ED) for adult patients with acute respiratory infections (ARIs) on the hospital length of stay (LOS), antiviral and antibiotic use during influenza seasons or future waves of COVID-19; … |
LAM PUI KIN; | 2025-03-28 |
| 94 | Evaluation of The Diagnostic Performance of The DM-DIV (in Vitro Diagnostic Medical Device) TestNPass for The Diagnosis of SARS-CoV-2 Infection Using A Nasopharyngeal Sample PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The COVID-19 pandemic has created a major global health crisis that requires a rapid and effective response, particularly in the field of diagnostics. The first tests used, based on PCR (polymerase chain reaction) performed through a deep nasopharyngeal swab, have shown their limitations in controlling the epidemic. The current need is to develop new tests that are rapid, affordable and easy to use, and that can be used on a large scale in outpatient settings to reduce the burden on healthcare teams. In addition, … |
UNIVERSITY HOSPITAL GRENOBLE | 2025-04-08 |
| 95 | The Effects of Lactococcus Lactis JCM 5805 (LC-Plasma) Lactic Acid Bacteria on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Disease in Australian Healthy Adults. Randomized Placebo-controlled Double-blind Parallel Group Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to evaluate the effects of LC-Plasma on the innate and acquired immune systems, including the activation of pDCs, which play a role in virus elimination, as well as to assess its efficacy in reducing clinical symptoms of upper respiratory infectious diseases in healthy adults. Researchers will compare LC-Plasma to placebo, participants will take a tablet containing LC-Plasma or placebo daily for 4 weeks. |
RDC CLINICAL PTY | 2025-11-18 |
| 96 | Evaluating The Neuromodulatory Effect of Ketamine in Long COVID: A Pilot Study Targeting Fatigue and Neurocognitive Symptoms PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Plain Language Summary: This study is a clinical trial to see if ketamine can help treat symptoms of Long COVID, especially fatigue and problems with thinking clearly (often called brain fog). Long COVID is a condition that affects people even after they have recovered from COVID-19, causing ongoing health issues like tiredness, memory problems, and difficulty concentrating. Right now, there are very few treatments available for these symptoms, … |
WILLIAM MICHAEL BRODE; | 2025-12-22 |
| 97 | Secondary Databased Post-marketing Surveillance Study of BNT162b2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is to assess the post-marketing safety of BNT162b2 products using nationwide population-based database in Republic of Korea. |
PFIZER | 2025-06-10 |
| 98 | SARS-CoV-2 Antibody-mediated Inflammatory Responses By Macrophages in Individuals With and Without Obesity PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths worldwide. As of 2024, the SARS-CoV-2 Omicron variant is the predominant strain circulating within the population, generally causing mild upper respiratory tract infections. However, hospitalizations and case fatalities due to COVID-19 continue, and there is a high probability that a new human coronavirus will emerge in the future. Understanding the pathophysiology of severe COVID-19 remains highly relevant, … |
DAVID S.Y. ONG; | 2025-05-16 |
| 99 | Effectiveness of BNT162b2 Annual Updated Formulations, Using Administrative Claims Data Tokenized to State Vaccine Registries Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to learn about how well the yearly updates to the COVID-19 vaccine work in adults (age 18 years and above) with a healthy immune system (the body’s cells, … |
PFIZER | 2025-11-19 |
| 100 | Impact of Nirmatrelvir-ritonavir on Changes in Healthcare Utilization and Frailty Following COVID-19: A Difference-in-difference Analysis PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: This is a cohort study that will include Paxlovid (nirmatrelvir-ritonavir) treatment eligible for people with a positive SARS-CoV-2 diagnostic test and at least one COVID-19 symptom. This study will look at the change in Post Covid Conditions measured by the number of outpatients, Emergency department, urgent care and inpatient visits before and after COVID-19 between those who did and did not receive Paxlovid. In addition, changes in frailty post-acute infection will be evaluated, in a separate analysis. It is hypothesized that individuals with COVID-19 who received Paxlovid will have a smaller post-COVID-19 increase (vs pre-COVID) in PCC healthcare utilization (i.e., … |
PFIZER | 2025-07-29 |
| 101 | A Phase II, Multi-centre Open Label Study to Assess The Efficacy and Safety of Oral Apabetalone With Background Dapagliflozin in Subjects With Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed SARS-CoV-2 infection, with symptoms within 3 months from the onset of COVID-19 that last for at least 2 months and cannot be explained by an alternative diagnosis. |
RESVERLOGIX | 2025-04-18 |
| 102 | Awake PROne Positioning in PatientS With Acute Hypoxemic Respiratory Failure in Germany – A Randomized Controlled Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Prone positioning has shown beneficial effects in intubated patients with severe respiratory failure and positive effects in awake patients with COVID-19 pneumonia. Conclusive evidence for patients with AHRF without COVID-19 is still missing. The investigators hypothesis that awake prone position in patients with AHRF is superior to standard supine/semi-recumbent position in terms of reducing the rate of tracheal intubation and/or all-cause death within 28 days after randomization. |
STEFAN KLUGE; | 2025-08-20 |
| 103 | Neurological Development in Toddlers After Maternal SARS-CoV-2 Infection During Pregnancy – A Follow-Up to The Covid-19 Related Obstetric and Neonatal Outcome Study in Germany (CRONOS) With A Dedicated Focus on Child Health PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is a virus that causes neurological symptoms in a significant proportion of patients in addition to respiratory symptoms. Intrauterine exposure to the virus has been demonstrated to exert a detrimental effect on the developing nervous system. However, developmental disorders frequently remain undetected until late infancy or early childhood. Consequently, there is a paucity of published data on neurodevelopment in young children following SARS-CoV-2 infection of their pregnant mothers. To this end, … |
MED. NADINE MAND; | 2025-05-13 |
| 104 | Impact of Functional and Cognitive Rehabilitation, in Adults with Chronic Noncommunicable Diseases and Long Covid-19 , on Their Functional and Cognitive Capacity, Quality of Life, and The Evolution of Their Baseline Condition, in Bogotá D.C PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate the impact of a functional and cognitive rehabilitation strategy compared to evidence-based informational messages, on functional capacity, cognitive abilities, quality of life, and disease progression in adults with chronic non-communicable diseases (NCDs) and Long Covid-19. Researchers will compare a structured rehabilitation program to informational support through evidence-based messages to determine if rehabilitation leads to better functional and cognitive outcomes in patients with Long Covid-19. Participants will be randomly assigned to one of two groups: 1. Functional and cognitive rehabilitation: Attending weekly in-person sessions for 8 weeks, … |
FUNDACIÓN CARDIOINFANTIL INSTITUTO DE CARDIOLOGÍA | 2025-03-11 |
| 105 | Community-based Behavioral Intervention to Increase COVID-19 and Influenza Vaccination for African American/ Black and Latino Persons: An Optimization Randomized Controlled Trial Related Papers Related Patents Related Grants Related Experts Highlight: The proposed study responds to the need for community-engaged interventions to increase vaccine uptake among populations experiencing health disparities. We focus on COVID-19 and influenza vaccination, both of which now require annual vaccines. Among those at highest risk for morbidity, hospitalization, and mortality are African American/Black and Latino (ABBL) persons who are not up-to-date on these vaccinations. Only 20-28% of adult AABL persons are up-to-date on COVID-19 vaccination, compared to 31% of White persons, … |
NEW YORK UNIVERSITY | 2025-04-29 |
| 106 | Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have symptoms that last long after the active infection ends. This is called long COVID. Sometimes, long COVID can affect the nerves and cause problems with sleep, thinking, the senses, and movement. Researchers want to find out whether people with long COVID have retained inactive remnants of SARS-CoV-2 in their bodies. Objective: To collect tissue samples to see if people with long COVID have remnants of SARS-CoV-2 in their bodies. Eligibility: People 18 years or older who have recovered from COVID-19, … |
AVINDRA NATH; | 2026-03-12 |
| 107 | A Phase 2 Trial to Evaluate Safety and Immunogenicity of A Next-generation COVID-19 Vaccine Delivered By Inhaled Aerosol to Humans PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to study the safety of a new inhaled vaccine to prevent COVID infection and learn about the immune responses that are made in the lungs and the blood after vaccination. Participants will be randomized (like the toss of a coin) to receive the experimental vaccine or a placebo (a look-alike solution that contains no vaccine). To be in the study participants will have to have already had three doses of a messenger ribonucleic acid (mRNA) COVID vaccine and be generally healthy. Participants are given a single dose of the vaccine by breathing in a fine mist that goes directly into the lungs. During follow-up participants will: * visit the clinic for checkups and blood tests at 2, 4 and 8 weeks after vaccination * report their symptoms for 24 weeks after getting the vaccine. In some participants, the researchers will collect cells from the lung 4 weeks after vaccination (a test known as a bronchoscopy). |
FIONA SMAILL; | 2026-01-26 |
| 108 | A Phase 2, Randomized, Observer-blind, Active-control Study to Evaluate The Immunogenicity, Reactogenicity, and Safety of MRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age. |
MODERNATX | 2025-10-20 |
| 109 | Dissecting Human Immune Responses To Infection With Influenza or SARS-CoV-2 PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the virus-specific immune response in people who are symptomatic with confirmed influenza or COVID-19. We will study the immune response of people who have and who have not been vaccinated with the seasonal influenza and COVID-19 vaccines within the past year. All participants will have data collected and blood, saliva, and nasal swabs performed at five separate visits; 1) at study enrollment, 2) on study day 7, 3) on or between study days 10 to 28, 4) on study day 90, … |
PHILIP MUDD; | 2026-03-12 |
| 110 | A Randomized Controlled Basket Study for Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction (RISE) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a prospective, randomized controlled, basket trial. Patients diagnosed with Post-Acute Sequelae of SARS-CoV-2 Infection who meet the inclusion and exclusion criteria are recruited and divided into three symptom clusters: Inflammatory Cardiac involvement symptoms cluster, cough symptoms cluster and fatigue symptoms cluster. Each symptom cluster is randomly divided into an experimental group and a control group, Patients who do not accept treatment can be included in the observational cohort. Subjects in the experimental group receive immunomodulatory interventions plus conventional treatment, … |
WEN-HONG ZHANG; | 2025-03-06 |
| 111 | Optimising General Practice Long COVID Care – Feasibility Trial of A Pilot Educational Intervention PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This trial will evaluate the feasibility of a pilot educational intervention for GPs that aims to enhance care and care outcomes among patients with long COVID at six general practices in the Ireland East region. Our first objective is to conduct focus groups with key stakeholders (GPs, other health professionals, patients, families/carers) that will inform the contents of an education intervention. The second objective will be to implement this educational intervention, and the third objective will be to determine whether the intervention is feasible. Study outcomes will include: – … |
WALTER CULLEN; | 2025-04-01 |
| 112 | EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is for patients suffering from COVID-19 pneumonia (mild to moderate cases) ; especially in developing countries where expensive drugs are not available. Colchicine is an economically favourable anti inflammatory drug readily Used for gout patients but is being given experimentally in Covid 19 patients . Study has been designed in this way that drug has been given carefully to patients on which there will be no to minimum side effects . It is only to see beneficial effects if any present in Covid pneumonia patients which will be observed by clinical \& lab improvement. |
ZAEEMA KANWAL; | 2025-09-04 |
| 113 | Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Mental health symptoms, including cognitive impairment (brain fog), following COVID-19 are of great concern to Veterans. This research seeks to advance understanding of the long-term effects of COVID-19 on neuropsychiatric and neurological functions, identifying clinically relevant biomarkers and directions for developing and testing therapeutic interventions. To accomplish these objectives the investigators are conducting a longitudinal study at two VA medical centers to: 1) assess and monitor cognitive function and psychiatric symptoms in Veterans post-COVID; 2) evaluate biomarkers of inflammation and signaling pathways associated with viral infection and neuropsychiatric function; … |
JENNIFER M LOFTIS; | 2026-03-31 |
| 114 | TELE-TOC: Telehealth Education Leveraging Electronic Transitions Of Care for COPD Patients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Transitions of Care (TOC) between hospital, ambulatory, and home settings for high-risk, frequently hospitalized adults with chronic diseases, such as chronic obstructive pulmonary disease (COPD) are complex, costly, and vulnerable to safety threats and poor health outcomes. One potential solution to address this gap in care is the Transitional Care Model (TCM), which utilizes a patient-centered approach with in-home interventions; since in-person in-home visits are costly, using innovative telehealth, such as virtual visits via teleconferencing may be just as effective with greater feasibility, scalability, and sustainability, … |
VALERIE G PRESS; | 2026-01-14 |
| 115 | Evaluation of MicroRNAs and Vitamin B12 Expression in Subjects with Neurologic Symptoms of Depression, Anxiety and Fatigue in Long COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: At the moment, the number of people with long COVID is unkown because there is still no effective diagnosis. This is why is very important to analyze the most common symptoms, which are: depression, anxiety and fatigue. This project seeks to analyze some blood components of people with long COVID, such as microRNAs and vitamin B12, in order to identify the body processes that changed after COVID-19 and thereby design better therapies and diagnostic methods focused on each of them. The hypothesis is that the expression of miR-21, … |
ALFONSO B. ALFARO; | 2025-03-07 |
| 116 | RECLAIM: An Adaptive Platform Trial for The Evaluation of Treatments for Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: RECLAIM is a Phase III, multi-domain, randomized, controlled, adaptive platform trial, designed to evaluate efficacy and safety of repurposed medications in patients with post-COVID condition (PCC). The trial started in the Netherlands in February 2025, comparing metformin, colchicine and usual care in an open-label domain. The information in this registration concerns that first domain in the Netherlands. A second domain, comparing minocyclin to a matching placebo, is expected to start in January 2026, also in the Netherlands. Trial-arms, additional domains and implementing countries may be introduced or terminated as the trial progresses. Participation is fully remote, using electronic consenting, … |
JANNEKE VAN DE WIJGERT; | 2025-12-12 |
| 117 | Investigating The Effectiveness of Vimida, A Digital Intervention for People Suffering From Post-viral Chronic Fatigue After COVID-19 Infection PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This randomized controlled trial (RCT) with 160 patients suffering from fatigue after COVID-19 infection aims to investigate the effectiveness of the unguided digital therapeutic vimida for reducing post-COVID-19 fatigue. Inclusion criteria are: male, female or non-binary, age ≥18 years, diagnosis of post-COVID-19 fatigue, ≥3 months since the last infection with COVID-19, fatigue severity score (cut-off) of ≥ 16 on the Chalder Fatigue Scale (CFQ-11), consent to participation, … |
JOHANNA SCHRÖDER; | 2025-06-18 |
| 118 | A PHASE 1/2 RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times. |
BIONTECH SE | 2026-01-26 |
| 119 | Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: A Single-center Comparative Analysis From China PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The project intends to carry out a retrospective study on the epidemiology, predisposing factors, clinical manifestations, diagnosis, treatment, prognosis and economic burden of mucormycosis in a Chinese single-center allogeneic hematopoietic stem cell transplantation population. The project was conducted at the Blood Diseases Hospital, Chinese Academy of Medical Sciences, which has rich experience in hematopoietic stem cell transplantation and has completed more than 3,000 cases of various types of HSCT, 400 allogeneic hematopoietic stem cell transplants per year, … |
INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINA | 2026-03-05 |
| 120 | Phase II Proof-of-concept, Randomized, Double-blind, Placebo-controlled Study to Evaluate The Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The study aims to prove that plitidepsin could be an efficacious, safe, and well-tolerated therapy for PCC. To this end, we will perform a randomized, double-blind study comparing the clinical and laboratory benefits of plitidepsin vs. placebo in 90 subjects with moderate to severe functional disability. The study consists of an intervention period and a follow-up period, with a total of 135 +/-3 days approximately between both periods. During the intervention period, four treatment cycles will be administered, scheduled every 15 days (every 2 weeks), with intravenous (IV) infusion over three consecutive days. After completing the intervention period, … |
FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA | 2026-04-03 |
| 121 | Study of Viral Respiratory Infections: Retrospective Evaluation of The Circulation of Respiratory Viruses, of Pathogenic-related Clinical Manifestations and of The Clinical Utility of Virological Diagnosis PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: Acute viral respiratory infections are a major public health problem, as they cause mortality especially in pediatric patients, over 65 and those with co-morbidities. The most frequently responsible viruses are: Influenza A and B, Respiratory Syncytial Virus, Adenovirus, Parainfluenza Virus, Metapneumovirus, Rhinovirus and SARS-CoV-2. By comparing clinical data and laboratory diagnosis among all categories of patients at greatest risk, … |
IRCCS AZIENDA OSPEDALIERO UNIVERSITARIA DI BOLOGNA | 2026-02-03 |
| 122 | Rehabilitation of Fatigue in Patients With Post-COVID-19 Syndrome PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: More than half of patients with post-COVID-19 syndrome experience fatigue. Rehabilitation is needed to treat this persistent symptom. The aim of this study is to conduct a rehabilitation intervention to treat patients with post-COVID-19 syndrome who experience persistent fatigue. |
IRENE TORRES SÁNCHEZ; | 2026-01-26 |
| 123 | Effect of Aerobic Training Versus Relaxation Techniques on Quality of Life in Patients With Post Covid-19 Irritable Bowel Syndrome PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study is to compare the effect of aerobic training and relaxation techniques on quality of life in Post covid-19 patients with irritable bowel syndrome . |
ALAE AHMED SALEM ISMAIL; | 2025-05-15 |
| 124 | A Phase 3, Randomized, Observer-Blinded, Study to Compare The Safety and Immunogenicity of 3 Lots of SARS-CoV-2 RS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix M™ Adjuvant in Participants ≥ 65 Years of Age Related Papers Related Patents Related Grants Related Experts Highlight: The goal of Phase 3 Study is Comparing the Safety and Immune Response of Three Batches of a COVID-19 and Flu Combination Vaccine in Seniors Aged 65+ |
NOVAVAX | 2025-03-11 |
| 125 | A Randomized Controlled Non-inferiority Trial of Placebo Versus Macrolide Antibiotics for Mycoplasma Pneumoniae Infection in Children with Community-acquired Pneumonia – The MYTHIC Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to compare a placebo (a look-alike substance that contains no active drug) with a commonly used antibiotic in children with Mycoplasma pneumoniae (a specific bacterium) induced community-acquired pneumonia. The main question it aims to answer is: Is antibiotic treatment needed in Mycoplasma pneumoniae (a specific bacterium) induced pneumonia? Participants will receive either a placebo or a antibiotic treatment and track their symptoms and vital signs until they are healthy. Researchers will then compare the length of symptoms between the placebo and the antibiotic group. |
CHRISTOPH BERGER; | 2025-02-12 |
| 126 | SARS-CoV-2 Safety Study for The Treatment of COVID-19 Related Papers Related Patents Related Grants Related Experts Highlight: SARS-CoV-2 produced strong pluripotent stem cells and brain cells to protect Telomere chromosomes to maintain Acid Deoxyribonucleic (ADN) Molecules. |
DO VAN TIN; | 2025-09-04 |
| 127 | DETERMINING THE IMPACT OF MICROBIAL DYSBIOSIS ON IMMUNE AND BARRIER DYSFUNCTION IN LONG COVID PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The SARS-CoV-2 virus causes COVID-19, which ranges from mild initial symptoms to severe multi-organ dysfunction. While some patients recover to their baseline states, others develop a long COVID, or post-acute sequelae of SARS-CoV-2 (PASC) consisting of symptoms persisting \>2-6 months post-infection. PASC symptoms include post-exertional malaise, fatigue, and heart palpitations as well as incident GI disorders, cognitive dysfunction, and arthritis. Based on prevalence/incidence studies, … |
LAVANYA VISVABHARATHY; | 2026-03-02 |
| 128 | An Open Short-term Clinical Pilot Trial on Safety and Immunogenicity of Nasal COVID-19 Vaccine at Different Dose Levels and Administration Methods PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing the SARS-CoV-2 spike protein. In this trial, the primary comparison in terms of safety and immunogenicity will be between two different dose levels of COV2 booster vaccine (low, high), and two different administration methods (nasal drops, nasal spray). In addition, COV2 vaccine will also be evaluated in vaccine naive subjects. |
ROKOTE LABORATORIES FINLAND OY | 2025-12-08 |
| 129 | Assessing A Multicomponent Intervention to Improve Quality of Life in Individuals With Long COVID-19 (COVIDL/MIQoL): A Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to assess the effectiveness of a multicomponent intervention in individuals with Long COVID. The main questions it aims to answer are: * Does the intervention increase quality of life, mental well-being, resilience, and physical condition in individuals with Long COVID? * Does the intervention decrease anxiety, depressed mood, and fatigue in individuals with Long COVID? The researchers will compare the multicomponent intervention with a control (non-intervention) group. Participants will: • Participate in a multicomponent intervention for 9 weeks (2 sessions each week, one of psycho-education and one of physical rehabilitation). |
MARIA LLISTOSELLA; | 2026-01-16 |
| 130 | Analysis of Single Respiratory Viral Infections Versus Co-infections in The Post-pandemic Era: Prevalence and ICU Needs in Hospitalized Adults PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of our study is to investigate the prevalence of viral respiratory infections in inpatients following the end of the pandemic. Additionally, the prevalence of patients co-infected with multiple viruses simultaneously will be assessed. In the secondary part of the study, the development of respiratory tract infections, the need for intensive care, and mortality rates within seven days will also be evaluated, and risk factors for patients with a more severe clinical course will be statistically calculated. |
ÖZLEM GÜLER; | 2025-07-08 |
| 131 | The Trial Uses Medicinal Herbs to Direct T Cells to Engulf The COVID-19 Virus and Protect The Organs Well PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The human immune system is designed to protect individuals from external sources of infection and internal cell mutation. It works effectively and efficiently until inflammation disturbs its functioning. Once compromised by inflammation, the immune system loses its capacity to recognize antigens and dependably defend the body against disease and illness. When COVID-19 invades humans, it causes an immune-storm (cytokine-storm) that can directly damage the organ(s), leading to death. The virus is an antigen – a trigger – but it is not the actual reason that causes organ failure and death; instead, … |
WANZHU HOU; | 2025-02-19 |
| 132 | Evaluation of Concordance Between An Innovative Test on Exhaled Air (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2 in Symptomatic Patients or Closed Contacts PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: During the COVID-19 pandemic, testing primarily relied on the use of nasopharyngeal swabs to detect the SARS-CoV-2 virus, responsible for the disease. However, this technique has several limitations, including the variable quality of swabs, its invasive nature, and arbitrariness in the choice of the number of cycles. Furthermore, it does not allow for the detection of viral proteins. To overcome these limitations, researchers developed the eBAM-CoV test, patented for the detection of viral proteins in the exhaled air of COVID-19 patients. This portable device provides an immediate assessment of the viral load with both quantitative and qualitative results, … |
CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES | 2025-03-24 |
| 133 | Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to evaluate the performance of the COVID/Flu Detect™ Rapid Self-Test when used in a home-like setting by lay users. The COVID/Flu Detect™ Rapid Self-Test is an investigational device intended for the qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens in nasal swab samples. Participants who are aged two (2) years and older and have symptoms of respiratory illness consistent with SARS-CoV-2 and influenza infection may be enrolled. Participants will use the COVID/Flu Detect™ Rapid Self-Test to self-collect, self-test, … |
INBIOS INTERNATIONAL | 2025-05-22 |
| 134 | Longitudinal Assessment of Potential Immunologic Correlates of Risk and Protection Following COVID-19 Vaccination Comparing Remote and Site-based Specimen Collection (Feasibility, Validity, and Proof of Concept) PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This trial is designed to assess immunological biomarkers measured from blood samples that can be used to reliably predict how well vaccines work against symptomatic COVID-19 as well as to evaluate the feasibility of remote, self-collected specimens when conducting a correlates analysis. For a lot of research studies, people need to go to the study doctor’s office regularly. For this study, we want to see if it is okay that people do the study doctor visits virtually, fill out questionnaires electronically, … |
BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY | 2025-09-17 |
| 135 | Improving COVID-19 Vaccine Uptake Among Racial and Ethnic Minority Groups With Rheumatic Diseases PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The overall goal of this study is to determine whether a novel, multi-modal, patient-directed behavioral intervention initiated in rheumatology clinics is an effective approach to improve uptake of updated COVID-19 vaccine. |
MARIA DANILA; | 2025-12-15 |
| 136 | A Phase 1 Study to Assess The Effect of Carbamazepine on The Pharmacokinetics of S-892216 in Healthy Adult Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of this study is to investigate the effect of multiple-dose administration of carbamazepine on the pharmacokinetics of S-892216 in healthy adults. |
SHIONOGI | 2025-03-11 |
| 137 | A Non-interventional, Prospective, Cross-sectional Study of The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With The Post-acute Phase of The Infection By Sars-Cov-2 PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: More than 660 million cases of COVID-19 have been reported worldwide, with 183 million cases in the EU alone. In several people, after recovery, the effects of the first waves of COVID-19 persisted beyond the acute phase and increased the risk of chronic multiorgan symptoms and disease. Up to 70% of people affected by COVID-19 showed reduced organ function even four months or more after COVID-19 diagnosis. Such a functional decline is associated with an increased risk of the development of non-communicable diseases (NCDs). Thus, there is an essential need for a better knowledge, tools, … |
HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS | 2025-11-17 |
| 138 | A Randomized, Observer-Blinded, Active-Controlled Study to Evaluate The Safety and Immunogenicity of A COVID-19 Influenza Combination Nanoparticle Vaccine and A Standalone Trivalent Nanoparticle Influenza Hemagglutinin Vaccine in Participants ≥ 65 Years of Age PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine. The researchers conducting the study won’t know which vaccine each participant receives, ensuring their observations are unbiased. This study compares the new combination vaccine to an already available flu vaccine to see how well it works. It’s a large-scale, final-stage study designed to thoroughly check how well the vaccines trigger an immune response (immunogenicity) and how safe they are. |
NOVAVAX | 2025-07-18 |
| 139 | AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID-19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months. |
PFIZER | 2026-03-25 |
| 140 | A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA (CVXGA50) Intranasal COVID-19 Vaccine in Adults PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 434 healthy participants. |
HONG JIN; | 2025-11-05 |
| 141 | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate The Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults With COVID-19 at High Risk for Disease Progression PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-19, which can require a hospital stay or lead to death. Some people who are high risk for severe illness may be unable to take certain treatments for COVID-19 because they are not available to them, … |
MERCK SHARP & DOHME | 2026-04-03 |
| 142 | Characterization of The IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19 PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Type I interferon (IFN-I) production is triggered by the detection of viral molecules, such as strands of viral RNA or DNA, by receptors known as PRRs (Pattern Recognition Receptors) present on many cell types. These interferons are secreted in minimal concentrations but can activate neighboring cells to secrete over 700 proteins with antiviral properties (inhibition of viral replication, destabilization of viral membranes, etc.). Thus, the IFN-I response serves as the immune system’s first line of defense during a viral infection. Very early in the COVID-19 pandemic, several research teams, including ours, … |
JEAN-CHRISTOPHE RICHARD; | 2025-03-10 |
| 143 | Thymalfasin (Thymosin Alpha 1; Ta1) As An Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this research is to learn more about ZADAXIN® (trade name; thymalfasin generic; Ta1 for short) and determine if Ta1 has any benefit in increasing the immune response to the COVID-19 vaccine. Ta1 has been shown to stimulate the immune system to fight infections. This research study will test the safety and possible harms of Ta1 when it is given to people at different dose levels before COVID-19 vaccination. |
THE METHODIST HOSPITAL RESEARCH INSTITUTE | 2025-07-31 |
| 144 | The Effects of Qi-gong on Physiology and Quality of Life in Patients with Post-acute Sequelae of Covid-19 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to determine whether Qi-Gong can improve physiological function and quality of life (QoL) in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC). Study Objectives: To assess whether Qi-Gong improves physiological function in individuals with PASC. To evaluate whether Qi-Gong enhances quality of life in individuals with PASC. Study Design: If a comparison group is included, researchers will compare Qi-Gong with standard care to assess its effectiveness. Participant Involvement: Practice Qi-Gong three times per week for three months. Record physiological data monthly. |
MEI-HUA WANG; | 2025-03-17 |
| 145 | An Exploratory Study to Establish The Dose, Safety and Pathogenicity of A SARS-CoV-2 Omicron Challenge Strain (BA.5) in Healthy Participants 18 to 40 Years of Age PF:2 Related Papers Related Patents Related Grants Related Experts Abstract: This is an exploratory study of an SARS-CoV-2 Omicron (BA.5) challenge strain to determine the optimum safe infectious titer of challenge agent in healthy participants 18 to 40 … |
MELISSA BEVAN; | 2025-11-21 |
| 146 | Potential Role of Diaphragmatic Muscle Weakness As A Cause of Persistent Exertional Dyspnea in Patients With COVID-19 Disease Without Hospitalization PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Fatigue and exercise intolerance after survived COVID-19-infection might be related to weakness of the respiratory muscles. The aim of the project is to measure respiratory muscle function and strength in our respiratory physiology laboratory in patients who were not hospitalized during the acute COVID-19-infection but still complain of different persistent symptoms including exertional dyspnea and fatigue. |
JENS SPIESSHÖFER; | 2026-01-28 |
| 147 | Virtual Intervention and Direct Assessment (VIDA) of Social Determinants of Health in Southern Minnesota Latino Communities After Coronavirus Disease 2019 (COVID-19): A Pilot Study. The VIDA After COVID Study Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to objectively identify and address social determinants of health (SDOH) priorities and barriers in Latino patients who survived or are vulnerable to COVID-19, and to understand the consequences of COVID-19 survivorship in local Latino communities. |
ALICE GALLO DE MORAES; | 2025-03-25 |
| 148 | Estimated Vaccine Effectiveness (VE) and Durability of Pfizer/BioNTech 2024-2025 COVID-19 (Coronavirus Disease 2019) Vaccine Related Papers Related Patents Related Grants Related Experts Highlight: This study is a retrospective case control analysis on the real-world effectiveness of the Pfizer-BioNTech BNT162b2 vaccine (2024-2025 formulation) against symptomatic SARS-CoV-2 infection among CVS MinuteClinic patients testing for SARS-CoV-2, across different age groups, during periods of various variant circulation, and by months since receipt of vaccine dose. |
PFIZER | 2025-11-06 |
| 149 | The Immunogenicity and Safety of COVID-19 and Influenza Vaccine Co-administration and Interval in Immunocompromised Hosts PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC). The main questions it aims to answer are: 1. Is co-administration of seasonal inactivated influenza vaccine (IIV) with the most up-to-date recommended COVID-19 booster dose non-inferior in inducing a 1-month peak protective humoral response against COVID-19, … |
RUTH SAPIR-PICHHADZE; | 2026-03-10 |
| 150 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess The Safety and Immunogenicity of A Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of A Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Study VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States. The purpose of the study is to assess the safety and immunogenicity of IIV-HD (high-dose inactivated influenza vaccine) + rC19 (adjuvanted recombinant COVID-19 vaccine) vaccine comprised of IIV-HD combined with different recombinant Spike (rS) antigen levels of rC19 compared to IIV-HD alone, rC19 (dose 1) alone, and IIV-HD and rC19 (dose 1) (coadministered in opposite arms). Placebo will be coadministered in the IIV-HD alone, rC19 (dose 1) alone, … |
SANOFI | 2025-04-01 |
| 151 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess The Safety and Immunogenicity of A Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of A Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Study VBT00002 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States. The purpose of the study is to assess the safety and immunogenicity of recombinant influenza vaccine (RIV) + adjuvanted recombinant COVID-19 vaccine (rC19) vaccine comprised of RIV combined with different recombinant Spike (rS) antigen levels of rC19 compared to RIV alone, rC19 (dose 1) alone, and RIV and rC19 (dose 1) (coadministered in opposite arms). Placebo will be coadministered in the RIV alone, rC19 (dose 1) alone, … |
SANOFI | 2025-05-28 |
| 152 | Human Factors and Clinical Validation of The IHealth Labs Inc IHealth Flu A&B/COVID-19/RSV Rapid Test in Anterior Nares Nasal Samples For Over The Counter (OTC) Use PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this observational study is to evaluate the diagnostic performance of an investigational Flu A/B, COVID-19 and RSV test in patients with signs and symptoms of respiratory infection. The main questions it aims to answer are: 1. What is the sensitivity and specificity of the investigational test compared with an FDA-cleared reference method for detection of Influenza A, Influenza B, , SARS-CoV-2 and respiratory syncytial virus antigen. 2. What is the overall positive and negative percent agreement between the investigational test and the reference method? Participants will: 1. Provide a respiratory specimen (e.g., … |
IHEALTH LABS | 2026-01-08 |
| 153 | Covid-19 Data Analyses in Brazil. Retrospective Study Using An Open Data Plataform (DataSUS) to Describe and Analyze Patient Characteristics and Covid-19 Outcomes in Brazil PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: This descriptive study aims to describe the Brazilian scenario of patients hospitalized due to COVID-19 and to analyze the impact of COVID-19 on the Brazilian public health system. Data will be extracted from the largest secondary database of the Brazilian public health system, DATASUS (Departamento de Informática do Sistema Único de Saúde), responsible for collecting, processing, analyzing and disseminating health information and statistics in the country. The analysis, performed only on patients hospitalized during the hospitalization episode, will also evaluate the impact of vaccination against COVID-19 on the immunocompromised population compared to the general population. |
ASTRAZENECA | 2025-09-18 |
| 154 | Evaluation of IHealth COVID-19/Flu A&B Rapid Test for SARS-CoV-2 and Flu A&B Detection in Symptomatic Individuals PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This observational study aims to evaluate the diagnostic performance of an investigational Influenza A/B and COVID-19 test in patients presenting with signs and symptoms of respiratory infection. The main questions it aims to answer are: 1. What is the sensitivity and specificity of the investigational test compared with an FDA-cleared reference method for detection of Influenza A, Influenza B, and SARS-CoV-2 antigen. 2. What is the overall positive and negative percent agreement between the investigational test and the reference method? Participants will: 1. Provide a respiratory specimen (e.g., … |
IHEALTH LABS | 2026-01-08 |
| 155 | A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed. The study lasts about 6 months, and participants need to visit the research site at least 3 times. |
BIONTECH SE | 2025-08-15 |
| 156 | A Phase 1/2, Randomized, Controlled Study to Evaluate The Reactogenicity, Safety, and Immunogenicity of An Investigational Flu Seasonal/SARS-CoV-2 Combination MRNA Vaccine in Adults PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine. The flu portion will target multiple strains of the flu virus, while the COVID-19 part will focus on the spike protein of the SARS-CoV-2 virus. Both parts of this vaccine have been tested individually before. This will be the first study to test the combined vaccine in humans in healthy adult participants. |
GLAXOSMITHKLINE | 2025-09-11 |
| 157 | ImProving Respiratory Outbreak Mitigation Through Point-of-care Testing in Long Term Care (PROMPT-LTC): A Cluster Randomized Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Outbreaks of seasonal respiratory viruses can spread rapidly in long-term care homes. Timely results for diagnostic tests remains a challenge for respiratory viruses due to the logistics of using a reference laboratory with delays leading to missed opportunities to implement virus-specific control measures to interrupt transmission resulting in larger outbreaks. Use of a point-of-care testing platform is a potential solution that provides faster results, but it is uncertain whether this translates into benefits for long-term care residents. This trial aims to assess whether rapid test results for respiratory pathogens (Influenza, … |
MICHAEL GARRON HOSPITAL | 2025-12-02 |
| 158 | Improving Health Status in COVID-19 Long-Hauler Through An Activity Coaching Programme: A Randomized Control Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This randomized clinical trial investigates the effects of a distance physical activity coaching program on the health of COVID-19 long-hauler. The study evaluates the impact of individualized coaching interventions to improve participants’ physical activity and quality of life. |
MARIE CARMEN VALENZA; | 2025-01-20 |
| 159 | A Non-interventional, Prospective, Cross-sectional Study of Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection By Sars-Cov-2 PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Pneumonia, which can be acquired in the community (including influenza and COVID-19), is a leading cause of mortality. The risk of severe cardiovascular diseases events (stroke, myocardial infarction, pulmonary embolism) increases after infections, but causal mechanisms are not understood yet. There is an essential need for improved understanding of the relationship between pneumonia and cardiovascular diseases and early identification of patients at risk of cardiovascular events to develop tailored therapies. The overall concept underpinning Homi-lung is to investigate the time course of host-microbiome interactions during \&amp; after pneumonia to i) understand the causal relationship between trained immunity, … |
HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS | 2026-02-17 |
| 160 | Work Productivity Losses in The United States Among High-risk Patients With COVID-19 During Acute and Longer-term Follow-up in An Omicron Predominant Period (PULSE-US) PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to understand how COVID-19 affects people’s ability to work and to calculate the costs associated with loss of work. The study compares two groups of participants who are confirmed to have mild-to moderated COVID-19 and who have high chances of the disease becoming severe. The two groups are: People who took the antiviral medication nirmatrelvir-ritonavir (also called Paxlovid) People who were eligible to receive antiviral medication but did not receive any. The participants will be selected from various health databases in the US between June 2021 and December 2022. The main goals are: To look at the characteristics of both groups of participants with COVID-19. To measure how much work these participants missed, including days off and sick leave, and the costs associated with this work loss. To compare work loss and costs between the two groups of participants, considering differences in their clinical and demographic characteristics. The study will evaluate at least 30 days of data from participants after they are confirmed to have COVID-19 |
PFIZER | 2026-02-09 |
| 161 | Virus-induced Immunosuppression Via Infection of Hematopoietic Progenitors PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis. |
CLAUDE CAPRON; | 2025-03-20 |
| 162 | Evaluation of A Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: The study will test two tactics to improve uptake of two vaccines in adults. The vaccines prevent COVID-19 and influenza. Both are common and harmful. Most adults do not get either vaccine. This is despite strong recommendations that all adults get both vaccines. The study will involve adult patients at eight Mayo Clinic primary care practices in Rochester and Kasson. The study will test the two tactics together. Four clinics will get the two tactics. The other four clinics will not. The study will randomly assign the two tactics to the clinics. One tactic is to send a letter by US mail to the patient. The letter will state strong recommendations on getting both vaccines now. It will tell patients how to get the vaccines now. The second tactic is to send monthly emails to clinicians. It will remind them to use every visit to vaccinate patients against COVID-19 and influenza. The study will compare the uptake of the two vaccines after six months in the clinics with and without the two tactics. |
LILA J. RUTTEN; | 2025-08-05 |
| 163 | Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (REVERSE-LC) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID. |
WES ELY; | 2026-03-27 |
| 164 | A Longitudinal Assessment of Serology and Effectiveness to Determine COVID-19 Vaccine Correlates of Risk (CoR) and Correlates of Protection (CoP) in A Heterogeneous US Population Through Use of Decentralized Sites and Approaches for Data/Specimen Collection PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Despite the availability of vaccines, there remains a need to identify specific immune responses that correlate with protection against SARS-CoV-2 infection. Additionally, the operational capability of retail pharmacy infrastructure to collect longitudinal data and biological samples needs to be assessed. This study aims to fill these gaps by determining correlates of protection (CoP), assessing the infrastructure’s capability, and examining demographic and geographic differences in participation. |
BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY | 2025-05-09 |
| 165 | Clinical Validation of The Aptitude Medical Systems Metrix COVID-19 Test for Detection of SARS-CoV-2 in Point-of-Care and At-Home (OTC)/Non-Laboratory Settings PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The Metrix COVID Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g., … |
APTITUDE MEDICAL SYSTEMS | 2025-10-02 |
| 166 | Pilot Study on The Feasibility of An RCT: Evaluating Periodic Fasting As A Treatment Strategy for Long Covid in Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Long COVID, characterized by persistent symptoms following acute COVID-19 infection, has emerged as a significant public health concern. Symptoms range from fatigue, cognitive impairments, to respiratory difficulties, affecting patients' quality of life. Dietary interventions, particularly fasting, have historically been used to modulate immune responses and improve health outcomes in various conditions. The Buchinger-Wilhelmi method represents a structured and medically supervised fasting approach. Given the inflammatory nature of long COVID, fasting may offer therapeutic benefits by modulating the immune response, enhancing cellular repair mechanisms, … |
JOCHEN SCHNEIDER; | 2024-12-30 |
| 167 | A Phase 3 Open-Label, Single-Arm Study to Evaluate The Safety and Immunogenicity of A JN.1 Subvariant SARS CoV-2 RS Vaccine PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The present study aims to investigate the safety and immunogenicity of the Novavax JN.1 subvariant vaccine SARS-CoV-2 rS adjuvanted with Matrix-M (NVX CoV2705) in previously vaccinated adults. A descriptive comparison will be made with participants who received the prior authorized vaccine NVX-CoV2601 in an earlier study (2019nCoV-313). |
NOVAVAX | 2025-07-18 |
| 168 | Korean Post Marketing Surveillance for Comirnaty Injection PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study is to identify any problems and questions with respect to the safety of Comirnaty Injection (Bretovameran) during the post-marketing period. |
PFIZER | 2026-01-14 |
| 169 | A Phase 2b, Double-Blind, Multi-Center, Randomized, Comparator-Controlled Trial to Determine The Relative Efficacy, Safety, and Immunogenicity of The Investigational Oral SARS-CoV-2 Vaccine Tablet Against Currently Approved/Authorized MRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19). In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain) vaccine. |
VAXART | 2025-10-22 |
| 170 | Text4Vax: Understanding The Effectiveness and Implementation of Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-2025 Season PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: This multi-site study assesses the impact of text message reminders on the receipt of COVID-19 and influenza text message reminders takes place primarily in practices from the American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) network. |
MELISSA STOCKWELL; | 2025-07-11 |
| 171 | SCreening FOr Malnutrition and Obesity in Patients With COVID-19 and Other Diseases PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: More than half of the Dutch population is overweight or obese, which is associated with an increased risk of Covid-19 and worse outcomes during a Covid-19 infection. In addition, malnutrition and loss of muscle mass are often reported with Covid-19, as well as with cancer and other diseases. Malnutrition and overweight or obesity can coexist, even within the same individual. It is still unclear which mechanisms contribute to the worse outcomes of Covid-19 and other diseases in case of overweight, malnutrition, … |
MARIAN DE VAN DER SCHUEREN; | 2025-08-31 |
| 172 | Double-blind, Randomized, Placebo-controlled, Pilot Clinical Trial to Evaluate The Safety, Tolerability and Efficacy of Two Doses of A Conditioned Medium From A Co-culture of M2-macrophages and Fat-derived Mesenchymal Cells (PRS CK STORM) in The Modulation of The Cytokine Storm for The Treatment of Acute Respiratory Distress Syndrome (ARDS) Caused By SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of Monocytes and fat-derived Mesenchymal Stromal Cells (PRS CK STORM) in the modulation of the cytokine storm for the treatment of the acute respiratory distress syndrome (ARDS) caused by SARS-Cov-2, influenza A, … |
DAVID BERNAL; | 2025-08-07 |
| 173 | Treatment of Post-COVID-19 With Hyperbaric Oxygen Therapy: A Randomized, Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical try is to investigate the effect of hyperbaric oxygen therapy (HBOT) on symptoms, quality of life and absence of work through sickness in patients with post-COVID on short- and mid-term, as well as to identify biochemical mechanisms of action. The main questions it aims to answer are: – What is the clinical relevance of improvements of symptoms and quality of life after treatment with HBOT for post-COVID? – What are the changes in absence from work after treatment with HBOT? – What is the cost-effectiveness of treatment with HBOT? – … |
MEREL HELLEMONS; | 2026-04-01 |
| 174 | EbolaCov: A Phase IV, Single-centre, Single-blinded, Randomized Controlled Trial to Assess Safety and Immunogenicity of RVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrent With MRNA COVID-19 Vaccine Booster Doses in Healthy African Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Concurrent vaccination scheduling for key target populations in Rwanda, such as healthcare workers, may confer significant advantages in the provision of vaccine coverage to several infectious diseases. This is a phase IV vaccine trial that looks to establish if two licenced vaccines, the rVSVΔG-ZEBOV-GP vaccine for protection against Ebola virus and messenger ribonucleic acid (mRNA) COVID vaccine for protection against SARS-CoV-2 virus, given concurrently to self selected healthy adult volunteers confers an acceptable safety profile and immunogenicity response. |
CHRISTOPHER GREEN; | 2025-05-01 |
| 175 | A Multi-Site Clinical Evaluation of The LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The DiaSorin Molecular LIAISON® NES FLU A/B, RSV & COVID-19 real-time polymerase chain reaction (RT-PCR) assay is intended for use on the DiaSorin LIAISON® NES instrument for the in-vitro qualitative detection and differentiation of nucleic acid from influenza A, influenza B, RSV and SARS-CoV-2 virus from dry nasal swabs (NS) from human patients with signs and symptoms during the acute phase of respiratory tract infection in conjunction with clinical and epidemiological risk factors. The LIAISON® NES FLU A/B, RSV & COVID-19 assay is intended for use as an aid in the differential diagnosis of influenza A, influenza B, … |
DIASORIN MOLECULAR | 2025-05-01 |
| 176 | Comparison of High Vs Standard Dose Influenza Vaccines in Pediatric Solid Organ Transplant Recipients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV). Recent studies have investigated two strategies to overcome poor immune responses in SOT recipients: (1) administration of high-dose (HD)-IIV compared to SD-IIV and (2) two doses of SD-IIV compared to one dose of SD-IIV in the same influenza season. One study compared HD-IIV vs. SD-IIV in adult SOT recipients and noted that HD-IIV was safe and more immunogenic; however, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2025-03-21 |
| 177 | Impact of Reactogenicity of The 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in The United States PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine |
SARANG K YOON; | 2025-03-10 |
| 178 | Clinical Study on The Immune Response Characteristics of Novel Coronavirus and Influenza Virus Infection PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open-label, prospective observational study in people 18 years of age and older designed to track changes in the dynamics of the respiratory and peripheral blood immune response in people infected with influenza virus and new coronaviruses, and to resolve the characteristics of the virus-induced natural immune response. |
JIANYING HUANG; | 2025-06-30 |
| 179 | A Multicentre, Randomised, Prospective Study Investigating The Efficacy and Safety of An Essential Oil-Based Preparation Administered to Mild and Moderately Severe COVID-19 Positive Patients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study was to compare the efficacy and safety of the essential oil-based product in patients with mild to moderate symptomatic COVID-19 Positive infection confirmed by PCR. A computational simulation approach of the molecular interaction (binding) of the main components of essential oils exhibiting antiviral activity with known intracellular protein targets of SARS-CoV-2 (nsp5: Main Protease) was adopted as a rationale for this study. SARS-CoV-2, a single-stranded RNA virus, has four major structural proteins Spike (S), Membrane (M), Envelope glycoprotein (E) and Nucleocapsid (N) protein and non-structural proteins (nsp). These non-structural proteins, … |
KANAT TAYFUN; | 2025-09-15 |
| 180 | Boosting COVID-19 Vaccination Uptake Using Wastewater Surveillance: A County-Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Vaccinations are among the most successful and critical public health interventions. Despite the enormous protection that vaccines provide to public health, both delays and refusals of vaccines (vaccine hesitancy) are on the rise. Given that low vaccination rates present both an individual and community risk, … |
SYRACUSE UNIVERSITY | 2025-09-15 |
| 181 | Does A Prior COVID-19 Infection Affect Lung Dynamics During Thoracic Anesthesia? PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: SARS-CoV-2 has infected more than 776 million people worldwide, raising concerns about its impact on patients with lung cancer, the most common cancer in men and the second most common cancer in women. Previous studies have suggested that COVID-19 may worsen lung dysfunction in patients undergoing surgery and that the coexistence of COVID-19 and lung cancer increases the risk of complications and mortality. It has been recommended that surgery be delayed after COVID-19 infection to reduce postoperative risk. This study examined the effects of prior COVID-19 infection on respiratory mechanics in patients undergoing thoracic surgery for lung cancer. |
CIGDEM YILDIRIM GUCLU; | 2025-08-12 |
| 182 | Safety of Simultaneous Versus Sequential Administration of MRNA COVID-19 Vaccine and Inactivated Influenza Vaccine (IIV) in Pregnant Women PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a prospective, randomized clinical trial. During this study, pregnant women will be randomly assigned to receive IIV and mRNA COVID-19 vaccine either simultaneously or sequentially (7-14 days apart). All participants will receive an mRNA COVID-19 vaccine at Visit 1 (Day 1). Solicited local and systemic symptoms of reactogenicity will be assessed on day of visit for Visits 1 and 2 and daily during the 6 days following each visit using either electronic or paper symptoms diaries, … |
GEETA SWAMY; | 2026-01-15 |
| 183 | Investigation of COVID-19 Post-acute Sequelae in Patients from Hvidovre Hospitals Catchment Area, and in A Register of The Danish Population 2000-2026 PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Since the first SARS-CoV-2 cases in 2019, over 660 million COVID-19 cases have been reported globally, including 183 million in the EU. Up to 70% of those infected experience reduced organ function four months or more after a COVID-19 diagnosis, potentially increasing the risk of non-communicable diseases (NCDs). The post-acute phase (PAP) after COVID-19 (four months or more after the acute phase) can lead to impaired function in various organ systems, with a focus on the lungs, cardiovascular system, and kidneys. These three NCDs collectively impose a significant burden on individuals and society. Urgently, … |
OVE ANDERSEN; | 2025-03-12 |
| 184 | A Phase 3b/4, Open-label Study to Assess The Immunogenicity and Safety of MRNA COVID-19 Variant-containing Vaccine Formulations PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). |
MODERNATX | 2026-03-27 |
| 185 | Prognostic Evaluation of Red Blood Cell Distribution Width (RDW) in Severe and Critical COVID-19 Patients Monitored in The Intensive Care Unit PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study was to evaluate the prognostic significance of erythrocyte distribution width (RDW) in severe and critically ill COVID-19 patients followed in the intensive care unit (ICU). RDW is a parameter that measures the heterogeneity in red blood cell size and is associated with the pathophysiological processes of COVID-19, such as systemic inflammation, oxidative stress, and erythropoiesis disorders. This study investigated the relationship between RDW and the need for intubation and mortality, and its utility as a prognostic marker in COVID-19 patients. |
HATICE GÜNEŞ YEŞILOVA; | 2025-11-24 |
| 186 | Effectiveness of A Sustained-release Ammonium Chloride Formulation in Reducing The Viral Load of Patients With COVID-19 or Influenza PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a prospective, double-blind, randomized, comparative effectiveness pilot study evaluating the effect of a sustained-release ammonium chloride formulation (ACF) on viral load dynamics in adult patients with mild or moderate COVID-19 or seasonal influenza infection. Eligible participants are randomly assigned in a 1:1 ratio to receive either ACF (ammonium chloride with vitamin D) or a control formulation (vitamin D only) twice daily for 10 consecutive days. The primary objective is to assess the reduction of viral load measured by RT-PCR cycle threshold (Ct) values at baseline, Day 3-5, … |
NIKOLAOS DRAKOULIS; | 2025-11-28 |
| 187 | Investigating The Efficacy of OMT to Recover Olfactory Perception After COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: One of the most widespread symptoms of COVID-19 is loss of the sense of smell. There are very few treatments for helping individuals recover their sense of smell. Osteopathic manipulative treatment (OMT) may be a useful tool in helping people recover their smell perception. In this study the investigators test whether OMT can be used to help individuals recover their sense of smell if they lost it during COVID-19. |
THOMAS EITING; | 2025-08-01 |
| 188 | The Singapore Platform for Controlled Human Infections With SARS-CoV-2 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to conduct a safe SARS-CoV-2 Delta variant human infection challenge in adult healthy volunteers. The main objectives are to: * Induce laboratory confirmed infection in up to 70% of participants * Confirm the safety profile as measured by the occurrence of adverse events (AEs) and serious adverse events (SAEs) from the day of viral challenge (Day 0) up to Day 28 follow-up. Participants will be given the GMP-produced Delta SARS-CoV-2 virus via intranasal drops using the optimized conditions established in the Development of a SARS-CoV-2 Delta variant human infection challenge model (COVHIC002) Human Challenge Study being conducted in the UK. A safe and well-tolerated human challenge model with the SARS-CoV-2 Delta variant will be established in Singapore. This model will be used to accelerate next-generation vaccine development and to determine the factors associated with altered clinical and virological outcomes; correlates of protection; and targets for the development of novel vaccines, therapeutics, and diagnostics. |
BARNABY YOUNG; | 2026-01-12 |
| 189 | Scaling and Sustaining COVID-19 Vaccination Through Meaningful Community Engagement and Care Coordination for Underserved Communities PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will optimize, implement, and test the impact of our multicomponent health program that includes three primary implementation strategies (Cultural Weavers and co-creation, mHealth strategies using culturally meaningful text and voice messages, and care coordination). The investigators will use a participatory approach to engage community members in co-creating and optimizing our mHealth outreach and enhanced care coordination program components. The investigators will use a hybrid type 3 effectiveness-implementation sequential multiple assignment randomized trial (SMART) design to assess the impact of our multicomponent health program on implementation and outcome measures. |
NICOLE STADNICK; | 2025-07-15 |
| 190 | Surveillance of Respiratory Viruses in Healthcare and Animal Workers in The Netherlands PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Outbreaks with viruses occur continuously, and novel viruses or new variants of existing viruses can surface after a zoonotic event or human-to-human transmission. This project proposal is designed to detect early circulation of (novel) respiratory viruses in both symptomatic and asymptomatic participants, either by direct detection of the virus or changes in local or systemic immunity. Additionally, SENTINEL will provide information on infectivity and (protective) immune responses in viral outbreaks or vaccination campaigns. |
CORINE GEURTS VAN KESSEL; | 2025-09-05 |
| 191 | Identification of COVID-19 Infection From Measurement of Exhaled Breath PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The type and number of chemicals in exhaled breath are different in people with infection as compared to those without infection. In this study, the breath of people with and without COVID infection will be measured. Changes in the amount and type of chemicals in breath will be used to determine if an individual does or does not have COVID infection. If the measurements of breath are a reliable measure of COVID infection, this device may be used to rapidly screen people who are attending large public events (for example, … |
GEORGE DIAZ; | 2024-10-01 |
| 192 | A Dose Finding Human Experimental Infection Study With SARS-CoV-2 Omicron BA.5 Subvariant in Healthy Volunteers Immunologically Experienced Against SARS-CoV-2 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A phase 1, dose-finding open label clinical infection, safety and viral detection optimization in healthy volunteers immunologically experienced against SARS-CoV-2. |
HELEN MCSHANE; | 2025-11-18 |
| 193 | A Phase L Study to Assess The Safety and Tolerability of PET Imaging With [11 C]CPPC [5-cyano-N-( 4-( 4-[l L CJ Me1hylpiperazin-l-yl)-2-(Piperidin-l-yl)Phenyl)Furan-2-carboxamide] Radioligand and Magnetic Resonance (MR) Imaging in Patients With Long COVID Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to evaluate the safety of using the \[5-cyano-N-(4-(4-\[11C\]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide\] (\[11C\]CPPC) radiotracer in positron emission tomography (PET) imaging of people with history of COVID-19 infection, with and without symptoms. The investigators are also interested to see whether use of this radiotracer reveals imaging differences between patients with history of COVID-19 infection and still exhibiting symptoms or healthy patients with history of COVID-19 infection but exhibiting no current symptoms. |
LICIA LUNA; | 2025-12-23 |
| 194 | Addressing COVID-19 Vaccine Hesitancy in Rural Community Pharmacies Reducing Disparities Through An Implementation Science Approach PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to test if virtual facilitation (e.g., video coaching) increases rural pharmacists’ ability to implement COVID-19 vaccine hesitancy counseling when compared to a standard implementation approach (e.g., training and dissemination of implementation support tools) in rural pharmacies. The main question it aims to answer is if virtual facilitation improves fidelity to a newly developed vaccine hesitancy counseling intervention when compared to standard implementation. All participants will begin in the standard implementation condition, where they will complete a webinar on COVID-19 vaccinations and a 30-minute online training on vaccine hesitancy communication. After standard implementation, … |
DELESHA M CARPENTER; | 2026-01-21 |
| 195 | Cognitive Muscular Therapy for Patients With Long-COVID (Post COVID-19) and Breathing Pattern Disorder PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of the study is to test a treatment known as Cognitive Muscular Therapy (CMT) for reducing breathlessness and improving autonomic function in patients with long-COVID. |
UNIVERSITY OF SALFORD | 2025-12-02 |
| 196 | RECOVER-SLEEP: A Platform Protocol for Evaluation of Interventions for Sleep Disturbances in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospective, multi-center, multi-arm, … |
DUKE UNIVERSITY | 2026-01-22 |
| 197 | The Impact of Education on The Rehabilitation of Patients Hospitalized Due to Pneumonia With Confirmed COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The planned research will enable the assessment of rehabilitation’s effects using two pulmonary rehabilitation models: conventional and supplemented with an education program for patients hospitalized due to pneumonia with confirmed COVID-19. |
RENATA BORYS; | 2024-11-01 |
| 198 | Vitamin D3, Mouthwash, Saliva Testing, Covid-19, Antiviral Testing PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The PI’s goal of this \[interventional/clinical trial\] is to \[explore the antiviral properties of vitamin D3 on saliva samples collected before and after the use of a vitamin D3 mouthwash\] in \[ adult participants, both genders, with COVID-19 who tested positive on a swab test\]. The main question\[s\] aims to answer \[is\]: \[Assess the antiviral potential of a novel vitamin D-based mouthwash in COVID-19-positive participants\]. PI will compare both \[Control group: saliva only- before use of mouthwash\], … |
SARAH FETEIH; | 2025-07-16 |
| 199 | Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to reduce morbidity and mortality from COVID-19 amongst people who are detained in and work in correctional facilities. The overall objective is to identify feasible and effective interventions to improve vaccine uptake in correctional facilities and study the effectiveness of these interventions through rapid cycle, cluster randomized trials in the Pennsylvania prison system. |
LISA B PUGLISI; | 2025-11-21 |
| 200 | Phase 1/2 Study to Evaluate Safety and Immunogenicity of A Prophylactic Plasmid DNA Booster Vaccine Against SARS-CoV-2 [Covigenix VAX-002] in Generally Healthy Adults 18 Years and Older PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Currently, several vaccines are available to combat the COVID-19 pandemic. The persistence of SARS-CoV-2 globally requires the development of additional vaccines to aid in preventing further SARS-CoV-2 infections. Covigenix VAX-002 is a vaccine based off its predecessors VAX-001 and VAX-001-1b. All three are plasmid DNA vaccines that express key antigenic determinants from SARS-CoV-2 and use the Entos Pharmaceuticals’ Fusogenix proteo-lipid vehicle (PLV) platform. Currently, the safety and tolerability of VAX-001 and VAX-001-1b for primary vaccination following 1 or 2 doses are being investigated in a Phase 1/2 study (ENTVAX01-101). In Phase 1, … |
ENTOS PHARMACEUTICALS | 2025-12-16 |